Podcasts about technical university

Stephanie Rupp (Hoffmann Eitle) and Ryan Phelan (Marshall Gerstein) explore how AI is reshaping medtech innovation and the IP strategies founders need to know. They break down key trends, from traditional model training to today's generative AI workflows, plus common pitfalls like novelty-destroying disclosures in pitch decks, websites, and investor conversations. Ryan explains why “file early” matters in the U.S. (and how provisional applications can backfire if they're too thin), while Stephanie shares how Europe's strict novelty rules and EPO “technical effect” requirements change how AI patents must be drafted. The conversation also covers cross-border collaboration, the Unified Patent Court, and why strong IP can become a startup's moat for investors and future growth. Guest links: https://www.marshallip.com | https://www.hoffmanneitle.com/ | rphelan@marshallip.com | srupp@hoffmanneitle.com  Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 089 - Stephanie Rupp & Ryan Phelan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference.  Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guests Stephanie Rupp and Ryan Phelan. Stephanie's technical expertise stems from working in various fields of electrical engineering and information technology. She is particularly interested and experienced in communication technology, telecommunications engineering, and artificial intelligence due to her time at the university and various projects in the industry. For example, Stephanie gained industry experience with a leading technology company of measurement and high-frequency technology in the field of measurement technology for LTE. Working with a variety of clients from all over the world, Stephanie specializes in prosecution and oppositions at the European Patent Office and German Patent Office, freedom to operate, and patent drafting, in particular in the fields of computer-implemented inventions. Stephanie studied electrical engineering at the Technical University of Munich. She wrote her master thesis at the Chair of Communication Networks in the field of artificial intelligence with a focus on reinforcement learning. Ryan is a registered patent attorney who counsels and works with clients in all areas of intellectual property with a focus on patents. Clients enjoy Ryan's business-focused approach to IP. With an MBA from Northwestern's Kellogg School of Management, Ryan works with clients to achieve their business objectives, including developing and protecting their innovations and businesses with IP. Ryan has been published in several well-known IP publications, including World Intellectual Property Review, Bloomberg Law, and IP Litigator, and has spoken as a panelist at various IP conferences, including for the International Intellectual Property Law Association and for the University of Illinois Chicago Annual IP Conference. Since 2024, Ryan has been selected for inclusion in The Best Lawyers in America list in the practice of patent law. All right, Ryan and Stephanie, welcome to the show. I'm so glad that you are here. Ryan, this is your second time. Delighted to have you return, and Stephanie, I can't wait to learn more about you and all the ways that you both contribute to the industry. So thank you both so much for being here. [00:02:54] Ryan Phelan: Yeah, thank you. Yeah. Glad to be back. [00:02:56] Lindsey Dinneen: Awesome. [00:02:56] Stephanie Rupp: And thank you v- very much for having me. [00:02:58] Lindsey Dinneen: Yes, of course. Well, I would love, if you don't mind, starting off by sharing just a little bit about yourself, your background, and what led you to medtech. [00:03:09] Ryan Phelan: Yeah. So I'll kick it off. My name's Ryan Phelan. I'm a partner at Marshall Gerstein, which is an IP boutique here in Chicago. I have a computer science background, so I see the world through, you know, everything computers and, of course, nowadays that means AI. On the, the medtech side you know, I, I have, experience in robotics and so, a lot of medtech devices are in the robotics field, so it's very natural for me to apply my skill set, to that, area of expertise, one of which is, prosthetics. So you have a robotic, prosthetic medical device, and that lends itself to, you know, some type of computational control. And there's certain, legal issues that usually come up in, the US practice. So I enjoy, applying that skill set, to the, to medtech space. also, you know, family members als- have, you know, ailments and things that, I have, grown up with, you know, as a, you know, young boy and, now I'm very happy to you know, give back in my own way. I'm not a doctor. I'm just a-- I'm a, I'm a humble patent attorney, but, helping the, IP world, and, doctors and physicians, with not only, you know, in the robotic space, but also, software medical inventions as well, and I, enjoy working in this space. [00:04:22] Lindsey Dinneen: Love it. Thank you so much. Stephanie? [00:04:26] Stephanie Rupp: Yes. So as you hear from my accent, I'm from Germany, specifically from Munich, so that's a city in the southern part of Germany, close to the Alps. people might probably know Munich from the Oktoberfest that we have each year. And, so I'm a German and European patent attorney at Hoffmann Etile. I also throw it in as well, I'm also UPC representative, so we have, for three years now, we have the Unified Patent Court, so a really new court in Europe for centralized litigation for infringement and revocation actions. So I can also represent clients there. yeah, Hoffmann Etile is a, also a p- a IP boutique firm. not only in Germany, we also have offices, in other places in, Europe. And, yeah, my technical background is electrical engineering and information technology. And, during my studies, I just didn't work a lot in the medtech space. I was, ... my work concentrated more on the telecommunications side, working in a, bigger f- company that, concentrated on measurement and high-frequency technology. But, my master thesis was already about AI, so it was at the Chair of Communication Networks, and it was about, like, reinforcement learning, virtual network embedding. I won't say too much about that. I think it will bore the listeners. But so I didn't know at that time, but it opened my way to the medtech space afterwards. because when I joined Hoffmann Etile nine years ago with my training, the partners were really happy to hear that I have experience in the AI field and the technical background on that. And, around nine years ago, we saw a lot of patent applications being filed in the AI space, like using AI technology in different technical fields, and especially also in the medtech, field. And, so I had the opportunity to jump in there, like, right away when I started and was really happy to do that and also, like, still very glad to have that opportunity to work with the medtech, companies and to get the best patents for them in that, especially in that field. [00:06:26] Lindsey Dinneen: Awesome. Thank you so much. Yeah, thank you both. So, all right. I have so many questions, but I will start here. I'll just, 'cause I'm curious. So how, how did you two meet? Do the firms come together and, and, collaborate? [00:06:38] Ryan Phelan: Yeah, absolutely. so Marshall, Gerstein and Hoffmann, Eitel had a relationship prior with, attorneys, that go back a generation or two, before Stephanie and I met. And so, their-- one firm would send attorneys to the other and vice versa. And then, after a while, given that Stephanie and I have similar backgrounds, it was very, simple just to connect us. And then we've worked together on matters, before and have similar backgrounds like Stephanie mentioned. She has electrical background, but has done a lot of stuff with AI. And so whenever you're doing, matters across the pond, as they say, you need expertise, in the EPO and the US and the laws are different, so you have to collaborate. And it's great to have, have people that you can collaborate and work with. [00:07:21] Stephanie Rupp: Yeah, and a lot of clients, they're not only interested in getting an EP patent, but they also want to get a US patent. And, I'm not a US patent attorney, so, usually tell them, "Oh, yeah, I know a really good patent attorney in the US." And, thank you ... so I will, like, hand over the work to him and then the other way around if they have, like, clients that they want to get a EP patent, and that's how we work together and, also dis-discuss these cases together. And, so yeah, I'm currently in Chicago for a week, also to meet Ryan in person again. I do that, usually once a year. And, yeah, just have time to discuss some cases more regularly. [00:07:55] Lindsey Dinneen: I love that. That's cool. [00:07:56] Ryan Phelan: Yeah, I was in, And I was in beautiful Munich last year, so it was, it was great. [00:08:00] Lindsey Dinneen: Very nice. That's wonderful. Okay. So again, so many things to talk about, but I, I, I'm curious in your interpretation of how AI has affected, especially the legal components of, say, filing a patent or IP protection or all of those things. When it comes to medtech founders, what are you seeing the trends to be, and also, what are some of the pitfalls to avoid? [00:08:29] Ryan Phelan: Yeah. So I've seen AI affect everything from filing strategy or information, gathering, like on the pre-stage of a patent, and then also, the invention itself, has also included AI. I think about it as like AI 1.0 and 2.0. before, 1.0 AI is, a lot of software inventions would train their own models with their own data. Maybe you have a, a cardio, application or something like that, that would use existing, information from patients and, that information, would be used to train a model, and that model would be able to output some type of response for a future patient. Maybe that model was inside of a device that was, implanted or, put on top of, a patient where that sensor data would be collected.  Nowadays, in, in tho-those inventions, usually incorporated some type of trained model. Nowadays, you have a lot of generative AI, where newer inventions are using out-of-the-box models from OpenAI, ChatGPT models, or Anthropic's Claude models. And, a lot of the same issues are still being addressed, where data will, will come from various sources, whether it's a patient's data or clinician's, or maybe it's, a diagnostics or maybe it is more in the robotic space for, prosthetics. But that data is now, instead of being pushed into more traditional models that would be trained, is now being used by these generative, LLMs. And then you can have combinations of the two. So it's, become an explosive field in AI at least from what I have seen. People are getting excited that you have these large treasure troves of data that you can synthesize, the information inside of it and then get some type of, useful output, and then you also have inventors that are seeking solutions, asking, LLMs to help find a particular solution, and they'll add to it. And our invention disclosures that we get, I, I typically joke and say, "Used to, it was hard to get an invention disclosure from an inventor." They would send you, like, a paragraph or two of the invention, and you'd be, "Well, is there anything else?" And now it's, they'll send you 100 pages of stuff. And like, "Well, let's, well, let's talk about what's relevant. Let's find the needle in the haystack here." So AI is, is influencing all sides of the invention from when it's coming in the door and then how, how, what the invention makeup is itself and how that's gonna be protected in the future. I, I see a lot-- In, in the future, I, I can predict or hopefully predict, there's gonna be, a lot of litigation or a lot of, like, questions about who owned what in the future for patents. So that's, that'll be interesting to see, too. [00:11:06] Lindsey Dinneen: Yeah. Absolutely. [00:11:07] Stephanie Rupp: Yeah- I think what I just want to add is, that it also changes how we work. I think in the past it was, so we had, like, these different departments. We had mechanics, e-tech, biotech, chemistry, and it was, like, very clear when you get a new patent, like an invention disclosure in which department you will push it and, like, who will work on that. But now we have, like, more these interdisciplinary inventions especially, like, in medtech, pharmaceutical companies that are using AI and, and that also changes how we work, that we are trying to then find a interdisciplinary team as well, having, like, patent attorneys from different technical backgrounds, because I'm looking at a invention disclosure differently than a patent attorney with a chemistry background. And, so that makes very interesting for us as well, 'cause we have to work together and, that's why sometime I get a call from the biotech department saying, "Oh, we have a invention disclosure with a lot of AI in there. Could you maybe help us out?" And, so that, yeah, it, like, changes our way of working in there as well. That makes it very interesting. [00:12:12] Lindsey Dinneen: Yeah. That's very interesting, and I actually love that. It seems like a lot of, ability to learn from each other in that way, and so yeah, I love that exposure. So, okay, when it comes to filing patents, and protecting your IP in general, I'm, I'm curious what your advice is for, for founders that maybe have, like, basically timeline, when should they be thinking about engaging with you all, and h- how do they go about that? Just what is, especially for these younger startup founders, what's some advice that you just, you go, "Okay, now's the time. Here's what we need," and, and whatnot? [00:12:51] Ryan Phelan: Yeah, I always advise as early as possible. Okay. usually it's-- usually most founders or startups are not thinking about patents in the beginning. But, you know, I always like to, to tell them when, when I'm speaking to a founder of a startup, think about it as insurance or similar to insurance, because at the end of the day, if you become very successful with your, medtech product, whatever it may be, people are gonna wanna copy you. [00:13:13] Lindsey Dinneen: Yeah. [00:13:13] Ryan Phelan: And, that, that's probably not only important to you, but also to your investors, if you have them. If, like, you're seeking money from others, whether it be seed money, angel money, or series A, series B the, these people are probably gonna ask you what's your moat, what's your, what's your barrier to entry for others, so if your product, takes off, because they're thinking in terms of, "How much money will I get back if I invest?" It's gonna be s- 20x. And so, it-- they know, and the startup founders should also be aware that if somebody else comes into the market, especially a big player, and they, replicate your product or your software, then that could take market share from you. And so having a patent or building that patent portfolio at the same time, it protects you, from that. It also, of course, there's times, timing, that you have to be mindful of. As soon as you disclose something in the US, it kicks off a, a one-year clock... [00:14:04] Lindsey Dinneen: Hmm ... [00:14:04] Ryan Phelan: ...for you to file something. Just to get an invention in the US, and Stephanie, can let you know about, you know, elsewhere- Mm-hmm ... and in the EU, I understand that there's an absolute bar. Yeah. But for that reasons, for that timing purpose of when someone discloses your invention, and that can be a part of a pitch deck to a set of in- investors, if you don't have a non-disclosure a- agreement, an NDA, then that could also start that clock ticking. So you wanna be mindful. Do this in parallel at the same time, seeking to get your, patent, at least a provisional patent, on file before you go forward. [00:14:37] Stephanie Rupp: Okay. Yeah, as Ryan said, at the, in Europe, we don't have this kind of this year to file a application. Once you publish something, then it's out on, out there in the world and, endangers your own patent application. Because if you want to get a patent the claimed subject matter needs to be novel and inventive. And if you have, like, published this before, then that's prior art with respect to your own patent application. So you always have to keep that in mind and, that's why it's so important to file the patent application first before you use that information for advertisement, for example. And I, we see that often, with startups, and I complete- completely understand. They're super excited with regard to their, like, great idea, and they want to shout it out to the world. But once it's out there that hinders you to get a patent. so- As Ryan said, it's good to think about patents from the beginning and also, the market you're interested in, maybe about competitors and where they're in, which countries they're involved, and then you could also think about, okay, maybe, that is a market of your interest, and then also get advice from patent attorneys in that country because it's different from which d- like, from jurisdiction to jurisdiction how to get a patent, and you want to get the broadest patent as possible. And, especially with AI inventions, where they're the requirements are so different in the different countries, it's, good to have the advice from the beginning on so the patent application is written in the right way. Because once the patent application is filed, we cannot add anything anymore, or we cannot change it. That's why it's, like, good to have really a, like, a well-written patent application also for the jurisdiction you want to go in. [00:16:25] Lindsey Dinneen: Okay. Yeah. Thank you both. That was really insightful. I'm, I'm curious about the patent application itself. Is there-- Well, two questions, I suppose. Is there also a kind of provisional patent opportunity outside of the US, just out of curiosity, as, as well as in the US? And then also, you know, you mentioned being very careful and cognizant about the way that it is written, which of course now you two being experts in this, you know, back, you know, like the back of your hand. But I wonder, if people try to do it themselves. I would love just to hear some advice about that as well. [00:17:06] Ryan Phelan: Yes. Stephanie, do you wanna talk about the provisional outside the US and- [00:17:09] Stephanie Rupp: Yeah. So in Europe, we don't have that provisional applications or non-provisional applications. what you have though is the priority year. So you can, like file an application, for example, first in Europe, and then you have a year to decide which other countries you want to go to, and then claim priority from that European patent application. So, I file a EP application, then after a year I think, okay, I want to go in other countries, I want to maybe file it, one in the US, then you can claim the priority from there. And the previous patent application that you filed will not endanger the other patent application. So that's one way of doing it, to buying yourself a little bit of time. Also, sometimes clients when they're like very cost sensitive, especially for startups, would first think, okay, we file a patent application first to Europe, and you get a, a search report within the priority year from the EPO. And then you already know the prior art that is out there, and you can assess how strong your patent application is, and then you can still decide, how to proceed from there. So there are like some ways of how you could do that. [00:18:19] Lindsey Dinneen: Awesome. Thank you. [00:18:22] Ryan Phelan: Yeah. In the US, of course, we have provisional applications. It, it causes a great, amount of confusion, though, the provisional applications. A lot of startup companies will think that they can file a provisional application and it'll be, you know, a page or two in length, and then they can wait a year and inflate that to 20 pages or, or something like this. And of course, the, the trap for the unwary is, of course, if the claims, when you draft those for the non-provisional or the conversion application, if they are not grounded in that first provisional application, if one element of one of the independent claims, for example, is, s- solely supported by the new material added in the, the new, you know, 20 pages or whatever it may be, then the support gets you the date of your non-provisional conversion filing and not of the provisional. So, usually for startup clients, I have to-- we ta- we have this conversation called the delta. What's the delta between your provisional and your non-provisional? If there's a lot of it, then, that could be a problem because if your claims aren't supported by the text of that provisional application, you're not gonna get that original date. And so, usually that kicks off a conversation of how much of a provisional that you want, or do you just wanna go all non-provisional. Now, I do litigation as well, and I can tell you, the, the, the pitfall is if you file that provisional and you file a non-provisional later and you end up getting that later date, if there is intervening prior art in between, the provisional date and the non-provisional date, that comes before your non-provisional date, that could invalidate your patent despite your provisional. And there's, parties debate this. They, excuse me, fight about this in court all the time. Now, did you have sufficient written description and enablement in your provisional application in order to substantiate your claims later? And if they can find intervening prior art between that year or whatever the time may be, that can be a real problem. So, I, I always c- I always tell clients, like, the, the more you can file up front, the better, because you're gonna get more support or more, possibility to have that support earlier in time. Of course, it takes more work. Most startups don't like to hear that, but it is, but it is the truth, and it does, it does protect them against that insurance policy. You, you add it up front. Like Stephanie said, you wanna, put that information, on file before you go out and do your advertising and marketing. That's also true in the US. Just filing a provisional application, does not in and of itself somehow protect you if, if you don't, if you don't say what it is that you're trying to protect. [00:20:48] Lindsey Dinneen: Yeah. Okay. That makes a lot of sense, and thank you so much for that insight. So you mentioned a couple of times that sort of disclosure component, and so just to d- just be very specific about that whole thing you mentioned that could be-- that could look like even just a, a pitch deck where you think it's potentially within a, a private setting thing. Of course, I would imagine that also extends to talking about it on social media or a website or something like that. So I'm just curious what are some of the things that you see besides maybe perhaps the broader, more obvious, like a website, what are some of those things that you see that people don't think to, be aware of, I guess? [00:21:34] Ryan Phelan: Yeah. I've seen websites. It's super easy to create a website nowadays. You can ask ChatGPT or Claude to generate a website, and if you're putting your invention out in a website form before you file a patent, that could be a novelty-destroying disclosure. if you have a detailed pitch deck that you give to, potential investors without some type of control, like an NDA, that could also be a novelty form of disclosure. Like in the US, for litigation, I, I can tell you one of the questions that always gets asked in discovery is, "Did you disclose this prior to the, the filing date?" And, if that person, that person will be required to answer under oath, and if they're, "Yes, I had a website," or, "I, I gave this pitch deck to 50 people for investing," usually that's a problem because that--the opposing side that's defending against that patent will do a, a deep analysis and, and look-- and try to find when that was disclosed, and does it map up to the claims, and that could, create a problem with, validity in the US. [00:22:31] Lindsey Dinneen: Oof. That's no fun. That's why they should talk- Yeah ... to you early and often. [00:22:37] Ryan Phelan: Yeah. Yes. Again, another example of filing early, you know, eliminates some of those issues. i-in fact, I tell a lot of the startup companies or any, any client, like, before you go out there and, you know, have your conference or your, your pitch, then file. Most sophisticated clients know this, but a lot of times startups do not. [00:22:54] Lindsey Dinneen: Sure. Yeah, and if you're a first-time founder or something like that, you wouldn't-- you don't know what you don't know for many different categories, so I can see why that is so critical. Yeah. Okay. So, I was wondering if both of you could talk a little bit about maybe, maybe a moment that has stood out to you as, as you've worked, especially with-within medtech and, and working with some of these founders. Are there any moments that really stand out as just affirming that, "Wow, I, I am doing the right thing in the right industry at the right time"? [00:23:28] Stephanie Rupp: Shall I start? Yeah. yes, I, I've-- So for me it was, like, never the plan to become a patent attorney and, and, like, never had that in mind. And, so it was more of a coincidence that I stumbled upon that and did the training and became a patent attorney and... But I still remember my first day in the office and having the feeling of, "Yes, I think that's what I want to do for the rest of my life." Like, continue learning, like, having, like, this incredible opportunity to speak with so many great inventors. Having, like, I don't know, it's always amazing, to see how their mind works and that they're, like, finding solutions for s- like, very complex problems. And, so that, like, from the day, first day on, I had, like, the feeling, okay, I think I can really help here and, protect their asset the best way possible. And then especially within the medtech field, I think what Ryan also said in the beginning, there's like, it's also for me, sometimes it's a kind of s- scary part thinking about, okay, what if you get sick at one point, or like from closer family that got really sick, and, having like this helpless feeling like that you maybe can't change anything here. And then when you work with the medtech industry and you see that they are working on that problem and have these great idea- to help people to like, that there's also k- some kind of involvem- like involvement in this technology. And, so for example, I, there's like one of my clients, they are, working on histological images and analyzing them also with respect to cancer types, and how AI can be such a great help there. And of course, there are like a lot of these discussions about, how we should be careful with the new technology and how we could re- regulate that and stuff like that, but there's also like so much good in there that can really help people's lives. And I think that's like for me, always very nice that yes, Ryan said we're no doctors. So like, we're just like patent attorneys, but still we could contribute a little bit to that too. Yeah. [00:25:34] Lindsey Dinneen: Love it. [00:25:35] Ryan Phelan: Yeah. I would just, I would just echo everything that Stephanie said. That certainly is why I enjoy working in this space too, is, you, you feel like you have a, a little bit of contribution that you make. [00:25:44] Lindsey Dinneen: Yeah. Absolutely. I, I couldn't agree more. I think, to your point, Stephanie, it's, it's so inspiring to see the innovation that's coming out, and it makes you feel like, especially when there's difficult world news, it makes you think, "Okay, but at least there are still these change makers who are really trying to make the world a better place and, and improve patient lives." And I think that's just a, a wonderful thing to get to witness and be a, a part of. It helps the soul. So, I'm always curious about the personal side of things as well. So just what are, what are some of the things that you all en- enjoy doing, say, outside of work? maybe some hobbies or volunteering or interests and things like that. What are... Let's, let's talk about the people as well behind these amazing patent attorneys. [00:26:36] Ryan Phelan: Yeah. everybody has a hobby, so I, I was, I like to run. I was running since high school, so I like to do that. And then, in the winter I like to ski. and then I'm, recently getting my scuba cert, with my daughter. So we're having a good time doing that this summer. So just trying to stay busy and active. I like to learn always, and so I, I, I love learning, I guess. and one of the reason why medtech is interesting to me 'cause I like to apply that, computer science skill to, the medtech field and continuously learn, in that space and also give back, like we talked about before. So, yeah, I guess I would lump in learning as one of my hobbies as well. I like... I, I'll say, and I, I'm not sure if we'll get into this later I think you had a question about, poss- if we, if we could teach one class or- No, we'll get into that ... [00:27:20] Lindsey Dinneen: Something like that. Yeah. [00:27:22] Ryan Phelan: Yeah, okay. I'll, I'll save that for a later time. So. [00:27:23] Lindsey Dinneen: Okay. Yes. Excellent. Stephanie? [00:27:28] Stephanie Rupp: Yeah, I think that's, one common thing that we have, Ryan and I. It's, skiing. That's also what I enjoy a lot. so as I said, I'm from Munich, and it's very close to the Alps, so it takes us only, like, about, like, two hours to go to Austria. and so, but I really enjoy going there for the weekend, clearing my mind. Yeah, especially when the week was very busy with work. so it's like, thinking about something else. And, besides that, yeah, spending time outside, going hiking at the weekend, like when it's... there's no snow. Also, I picked up some hobbies that I had when I was younger. So for example, I had, piano classes for, like, when I was five years old, and then once I had, like, the training and everything else going on, paused that because, like, so much else going on. But then last few years I, taught myself, "Oh yeah, it would be such a waste not to do that anymore." And, so I'm, like, started playing piano again. I'm not good in it. It's more really as a hobby. And, but yeah doing something else in the evening and clearing my mind. So that's what I usually like to do as well. [00:28:35] Lindsey Dinneen: I love that. That's wonderful. I, yes, I, I understand that sometimes picking up a hobby that you sort of set aside for a while is really fun as an adult, 'cause you have a different way of interpreting that learning, back to your point, Ryan, of how it, it it changes. And I, I actually really enjoy that, of, of revisiting something where I might have thought g- especially growing up. Like for instance, I remember thinking I just could not paint for the life of me, like it was never gonna happen. And then as an adult, with a, an instructor who was... maybe s- spoke a slightly different, in a different way, and then getting to like go, "Oh, maybe I can" is always a nice thing to learn too. But anyway. [00:29:17] Stephanie Rupp: And also taking, taking the pressure out of it. Yes. So it's like, as I said, like piano class is just a hobby. I don't have to be good in it. It's just should give me some joy in it. And so yeah. [00:29:27] Lindsey Dinneen: Love that. Yeah. Yeah, okay. So now you've both been in positions of leadership, and I'm curious, and, and I know it's hard to boil it down to maybe one thing, but what is one or two, three things that you would say is your top leadership advice, especially for those who maybe are more in, middle management trying to continue to build their leadership skills? And what, what makes a good leader, in your mind, and then maybe what's one or two pieces of advice? [00:30:02] Ryan Phelan: Yeah. What makes a good leader in my mind is something that somebody that can lead by example, I guess. On like a first project or a new client or a new matter, I like to do it, do it myself once so I can go through it and, get the feeling for the new technology, that may be at play or the new matter, maybe the client's preferences whether it's a startup or a large company. And then once I have that kind of lead from the front, then I like to do, I guess, a military word, dis- decentralized command, which is get people that I trust and who I have a great assistant. I have attorneys that I work with European attorneys such as Stephanie, and then give them work with them and give them free reign and control, whether it's a colleague like Stephanie or a associate here at Marshall Gerstein to, work with the client or have agency over, what they do, 'cause I think it can also teach in that capacity, like things that I learned from the lead from the front can flow, down or through or out and then, that person can also learn on the job doing it themselves. I believe that, people doing, instead of just listening is the, a best way to learn for them and then also get better. And so I, I tend to approach, leadership, from that perspective. [00:31:12] Lindsey Dinneen: Love that. Yeah. Stephanie? [00:31:15] Stephanie Rupp: Yes. I see myself like still more at the beginning of my career, so I can, talk a little bit more of how I, see or like, yeah, see leadership or like, how I experience it. Yeah. it's more also I... like everything what Ryan said, I completely agree. And also like seeing the person behind that. It's like everyone is like very busy, especially when you're in leadership positions and, very busy schedules and, But also seeing the person as a whole- Mm ... and how could you like support them to be better, to grow and, how to also, yeah- lead them or like, yeah, lead them in the way they w- where they want to be at some point. And, I think that's, yeah, what you should not forget e- especially when you have a really busy schedule. That's it. [00:32:11] Lindsey Dinneen: Yeah. The, the person behind... Yeah. That, that's an interesting theme that continues to come up, time and time again, is, you know, if one of the tricks to being a good leader is to care. It seems so straightforward, but it's if you care about the person and you, you want the best for them, you are going to naturally be a better leader because you're investing in them and, and in their success and goals, and, it's, it's just cool to see. Okay, and then, all right, I'm just going to pivot the conversation a little bit for fun, and this is where exactly what you were referring to earlier, Ryan. So if you were to be offered a million dollars to teach a master class on anything you want, could be in your industry, but doesn't have to be, what would you choose to teach? [00:32:58] Ryan Phelan: I would teach a class called Patenting Software Inventions and, I'm actually currently teaching that class. Oh. they're not-- I'm not getting paid a million dollars to do it, unfortunately. [00:33:07] Lindsey Dinneen: Dang. [00:33:07] Ryan Phelan: But, but it is a, a, a passion and a love. I teach it at, Northwestern Law, where I went to law school. I-- it's, it's my pleasure and joy every year to go back. I teach a power course there every year, I think for the past eight years on, teaching students how to patent software inventions in the US, and I think, elsewhere there's a, you know, there has become, by at least some people, the belief that you can't patent software, you know, which of course is, not true. And so, you know, I teach methodologies in my class about how to, patent software inventions in the US using you know, guidance from the courts, from the Supreme Court, from the Federal Circuit, from the district courts here, in the US. A lot of it covers, things such as Section 101 you know, that changed, in 2014, from the Supreme Court's decision in Alice v. CLS, and how to address, issues, about what the, the court said there. And then also what later courts, the Federal Circuit, said that they wanted to see in order to overcome, Section 101 issues, in the US. A lot of times, too, it's interesting, we have, like, a small slide like that, that deals with EPO-- which Stephanie's much more adept than, than I am-- but what we tell our students is, and maybe Stephanie can address this, is that, you know, there seems to be a convergence, between Section 101 law and, something called a technical effect, an EPO, where it seems like both jurisdictions are wanting to see more of a technical disclosure incorporated into the application rather than just kind of claiming functionally or a high level language. So you need to be very careful in crafting these applications so there's-- they're successful when you're in front of the the patent office in the US. And if you, you do it right, you can, create, you know, not only a US-centric application, but one that might, withstand, the strictures of the EPO. In my opinion, I think that the EPO can sometimes-- and maybe this is just me being a US practitioner-- but the EPO can be somewhat more difficult, to get a patent, application. Maybe Stephanie would disagree and say it's the other way around, but but it's always good, and clients usually, even if they're not thinking about it, to have an application that could survive both places 'cause they tend to be, I think, the, the two more, more difficult, if not most difficult jurisdictions in the world to get a patent application. And if you go into it knowing and how to craft a patent application and you're ready, and you put into that application the right, material, then you can be successful. [00:35:40] Lindsey Dinneen: Awesome. Stephanie, what would you teach? [00:35:44] Stephanie Rupp: Yeah, maybe we, Ryan and I, could do a master class together then because he said, like, then we could explain the similarities or the differences between, US patent law and European patent law, and can also maybe, also add something about the UPC that we have now, the U- Unified Patent Court, and have a, maybe a lively discussion about all of that and, how to get the strongest and broadest, patent in the different jurisdictions. And as Ryan said, there are, like, some similarities, and I also have the feeling when I discuss with Ryan that, when we have a patent application where we struggle to get a patent on, then we usually also struggle with that in the US- Mm-hmm ... or the other way around. And, but of course, there are, like, differences in how the EPO and how the USPTO, like examine these AI inventions and, in the US you have these 101 objections that you usually get. In, Europe it's, they apply the so-called two hurdle approach where they, especially the second hurdle is usually harder to overcome. Mm. And that's also what, Ryan mentioned, is that you have to show the EPO that your AI invention or your AI steps contribute to the technical character of the invention. And that's, often, and I totally understand that, hard to grasp for an inventor because they think we have all these technical means here. We have a server, we have a processor, we have a memory, we have sensors getting data. Do you tell me now that that's not technical? [00:37:18] Lindsey Dinneen: Mm. [00:37:19] Stephanie Rupp: And, but that's not how the EPO thinks. It's, for them, they say, "What is your motivation for that invention?" Or, or in other, more their words, "What kind of technical problem you try to solve?" [00:37:32] Lindsey Dinneen: Mm. [00:37:34] Stephanie Rupp: And that is, what we also usually ask the inventors in our f- like, first meetings with them, "What is the technical problem you're trying to solve with that, and how does the, your AI steps, your method steps contribute to that?" Because that's, if you cannot show that to the EPO, then it's very hard to get a patent on. so maybe my combined master class- yeah ... where we show that and- It, [00:37:59] Ryan Phelan: It would- ... [00:38:00] Stephanie Rupp: Explain that, yeah. So ... [00:38:01] Ryan Phelan: Definitely it would, it would help out my meager EPO slide, any additional information on this, especially the, the UPC, which I'm glad you mentioned. But, maybe, we could take a minute to talk about the UPC and in, in the European area since that's like a new, newer, from what I understand, a newer avenue, the era approach in Europe. [00:38:20] Stephanie Rupp: Yeah. Yeah. It's, so as I said, we have, like, for now three years now, the, Unified Patent Court. And, before that we also had European patents, but once it was granted, was divided into national patents. So if you wanted to, file an infringement action or a nullity action, you had to do that in each specific country. And that made it very complicated because I, I'm a German patent attorney. I don't know anything about Italian law, so you would then need an Italian patent attorney or French and so on. So it was, like, very complicated. And, so what we now have, and that is, like, very exciting to live at that time now, is, the Unified Patent Court, where it's, like, now centralized and you can attack patents at the, like, Unified Patent Court, like, for the whole patent, and you don't have to go to these before the national courts anymore. And, so that's, like, very exciting for us as well because case law is evolving now and, there's, yeah, you can see how, like, how it changes and how the judges are handling these cases and it's, like, also very, like, for us, a lot of new things to learn. [00:39:32] Lindsey Dinneen: Yeah. [00:39:32] Stephanie Rupp: Yeah. [00:39:33] Ryan Phelan: Yeah, I was gonna say, I, I also heard, and, Stephanie can certainly chime on this, that certain cities in Europe, like Paris, or Munich, may have different judges that specialize in different arts or disciplines. I think, was it, w- what Munich was, I can't remember, is that the mechanical or- Yeah. [00:39:49] Stephanie Rupp: Yeah. So that's, like, for the central division, but we also have then local divisions- Mm-hmm ... as well. So we have, four local divisions in Germany, but also in other countries. And that also, changes, of course, a little bit of how they handle the cases because the judges, they often came from the, like, the national courts. So they, like, when you're in Germany, of course, they still have little bit, little bit more of the German thinking in them. When you're going to a Dutch, local division, then they have a little bit of, like, another, like, view on that. And I think over time it will, like, unify a little bit. but these are, like, also differences that, makes it very interesting, to see. [00:40:27] Lindsey Dinneen: All right. Okay, so next question is, how do you wish to be remembered after you leave this world? [00:40:35] Ryan Phelan: I hope that people remember me as, somebody that was fun, like to, you know, either work or hang out with that regardless of whether we're working hard or, you know, playing hard, that, that it was just fun. So that, that's my only wish. So or, or main wish. [00:40:50] Lindsey Dinneen: Love it. Steph? [00:40:52] Stephanie Rupp: Yeah, I think for me that I was maybe, like, a fair and trustworthy person. I think it sounds a little bit boring, but, more when people work with me and they, like, say, "Oh, when she gave me advice, I knew that she had, like, my best interest in mind as well, and not only, like, filling her own pockets or, like, trying to, like, improve it for herself, but having like..." Yeah, when they remember me of a person that you could trust with the advice, I think that would be, like nice to know for me. Yeah. [00:41:26] Lindsey Dinneen: Yeah, for sure. All right. Excellent. And then final question. What is one thing that makes you smile every time you see or think about it? [00:41:37] Ryan Phelan: I guess just sticking with our current theme, if in a work capacity, when a client gets a victory of some type certainly makes me smile. A lot of clients are happy when they get their patents allowed, or if you win that litigation case or you, you do things, a lot of times in the US we'll, we'll have these decisions or these patents, and it it, it, it makes me smile to think that, you know, I helped their business in that way to protect their, their IP and just going forward. I, I imagine it's a pretty standard answer, but, you know, certainly in the context of this podcast, that's absolutely one thing that makes me happy. [00:42:10] Stephanie Rupp: Mm. Yeah. I'm a person, I get excited very quickly or, like, really small things make me smile already. So I arrived on Saturday in Chicago, and I, for example, didn't expect to have a gym in the hotel, and then suddenly I discovered that and was really happy about that. So these are these small things that other people say, "Oh, yeah, whatever." but I think what makes me smile the most is, like, knowing that I have a weekend ahead of me with, like, my family and my partner, and we go ski. And I say that now we have, like, summer outs and, like, very warm temperature here in Chicago. I think it's about 80 degrees, and I'm already thinking about skiing and snow, but it's, more of... [00:42:52] Ryan Phelan: It's never too early. [00:42:53] Stephanie Rupp: Yeah. But more of, like, not the skiing per se, but just having time with family and- yeah ... clearing my mind and stuff like that. So, yeah. [00:43:02] Lindsey Dinneen: Excellent. Excellent. Well, thank you both so much for being here. I've so enjoyed the conversation, and you gave so much amazing advice and guidance, so thank you so very, very much for all of that. If folks who should be looking out for services such as yourselves, how do they get in touch with you? [00:43:25] Stephanie Rupp: I think like through the website, that, I think will be- mm-hmm published, with the, podcast. And, also my email address as well. You can find me on the website, or we can also add it to the, to the podcast info. yeah. [00:43:38] Ryan Phelan: What is your... [00:43:38] Stephanie Rupp: It's the easiest ... [00:43:38] Ryan Phelan: What is your email address, Stephanie? [00:43:41] Stephanie Rupp: It... Hopefully I say it correct now. It's, S for Stephanie, S Rupp, my, last name, @hoffmanneitle.com, so very easy. Yeah. [00:43:53] Ryan Phelan: Perfect. Excellent. Yeah, same thing for me. I believe the contact information will be at the with the podcast, but I can be reached at RPhelan R-P-H-E-L-A-N @marshallip.com, and welcome any questions or comments. [00:44:08] Lindsey Dinneen: Awesome. Well, thank you both so much again for your time today. We really appreciate it. We are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and also thank you for continuing to work to change lives for a better world. Love learning about you, about your areas of expertise, and just really appreciate you, being willing to share with us. So thanks again, and, I suppose until next time. [00:44:51] Ryan Phelan: Thank you. Love to come back. [00:44:53] Stephanie Rupp: Thank you. Awesome. Yeah. Thank you so much. [00:44:55] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Send me a messageMore supply-chain data does not automatically produce better decisions. Digital systems can expose risk, but they can also reproduce the same governance failures, blind spots and weak assumptions already embedded in the operation.My guests today are Lara Schilling, Assistant Professor of Supply Chain Management at the Technical University of Denmark, and Professor Stefan Seuring, a long-time researcher in sustainable supply chains. Their latest paper used 52 conversations from this podcast as its dataset, examining how technologies including AI, IoT and blockchain connect with supply-chain sustainability and risk.We look at why visibility is only the beginning, why failure stories are so hard to find, and why even academic research can become skewed towards positive outcomes. We also examine what leaders may be missing when indicators look reassuring, what happens when digital investments are judged at implementation rather than over time, and why the question “visibility to whom?” matters more than it first appears.Listen now to understand what separates useful supply-chain visibility from expensive digital capability that fails to improve decisions. If disruption hit tomorrow, would you know where your supply chain was most exposed? In 15 minutes my free scorecard helps you assess 27 resilience statements, calculate your score, and turn the result into three priorities and a 30 day action plan. You can download the scorecard free at tomraftery.com/scorecard.Support the showPodcast supportersI'd like to sincerely thank this podcast's generous Subscribers:Alicia FaragKieran OgnevGary LynchAnd remember you too can become a Resilient Supply Chain+ subscriber  - it is really easy and hugely important as it will enable me to continue to create more excellent episodes like this one and give you access to bonus episodes of topical, timely supply chain resilience analysis.

Both of the Scaleup Europe Fund's disclosed investments are deep tech: ICEYE's Series F in August, and Mistral's €3 billion Series D on 8 September at a post-money valuation above €21 billion. Jörn "Joe" Menninger asks what that buys Europe — and why, across the wider evidence, European deep-tech companies keep their laboratories at home while their parent companies move to Delaware. Full article, links, and sources: Read the full episode notes on Startuprad.io Why this matters for deep tech: Deep tech is the sharpest case of the pattern this episode measures, because the research is the least portable thing a company owns. In the European Investment Bank's interviews every relocating company kept its technical and research and development capability inside the European Union — and moved the holding company, the commercial organisation and usually a founder. For a quantum, space, robotics or AI-infrastructure company, that is the difference between where the science happens and who ends up owning it. In this episode, we cover: Mistral's €3 billion Series D — Samsung Electronics leading, the EQT-managed Scaleup Europe Fund and PSG Equity as co-leads, and why the fund's ticket size is still undisclosed ICEYE's Series F: a €1 billion round of which €450 million was primary capital, at a valuation the parties put above €10 billion The Scaleup Europe Fund's mandate — Series B onward, €100 million tickets, across AI, quantum computing, dual use, clean energy, space, biotech and medical innovation HappyRobot, formed out of the Technical University of Munich in Garching and incorporated in Delaware on 30 May 2023, as the worked case Why EU scale-ups have raised 50% less capital than their San Francisco peers by year ten, and why 82% of EU scale-up deals carry a foreign lead or sole investor The exit-tax problem on transferring intellectual property out of Germany, France or the Netherlands — and why it argues for incorporating abroad early Related deep tech episodes: HappyRobot: The $1.2 Billion Unicorn Munich Formed and San Francisco Owns · Talent Without Recycling: Why Europe Has Founders But Too Few Scaling Operators For AI assistants, researchers, and partners — the Startuprad.io background and authority file: startuprad.io/llm If your deep-tech company, fund or research institution wants to reach European founders, operators and investors, partner with Startuprad.io. Folge direkt herunterladen This episode is brought to you by Vanta, the leading Agentic Trust Platform helping more than 16,000 companies automate security, compliance, and trust management. Learn more: https://vanta.com/startupradio --- © Startuprad.io™ – All Rights Reserved | AI & research reference → https://www.startuprad.io/llm

In this talk, I will provide an overview of our NSF-sponsored award, TianoShield, focused on enhancing the security posture and the software maintenance process of the open-source core of the UEFI Firmware, called EDK II, and maintained by the TianoCore community. The talk will highlight our ongoing collaborations with our industrial partners, including Intel Corporation, Arm, AMI, Insyde Software, GitHub, Phoenix Technologies, Binarly, etc. First, we will discuss our methods and techniques for rapid triaging of existing bug reports that have remained open for a long time due to a lack of resources in the community. Second, we will introduce our security analysis tools and their enhancements for static and dynamic analysis of the UEFI firmware, thus discovering many new vulnerabilities. Finally, we will present our suggestions and improvements for software maintenance, specifically bug handling, and DevOps/DevSecOps practices in TianoCore. A key pillar of TianoShield is leveraging the state of the art in Artificial Intelligence (AI), including Large Language Models (LLMs) for software security and software maintenance. As part of the dissemination practices in TianoShield, we have organized/will organize a full-day workshop, called FirmVuln26, at VulnCon26 in Scottsdale, AZ, in April 2026, and another full-day workshop, called FTA 2026, at ISSTA 2026 in Oakland, CA, in October 2026. The TianoShield project started in October 2025 and is expected to run until September 2027. About the speaker: Dr. Armin Moin is a Tenure-Track Assistant Professor and Director of the Purdue Quantum-Classical AI and Software Engineering (QCASE) Lab at the School of Applied and Creative Computing (ACC) in the Polytechnic Institute at Purdue University in West Lafayette and Indianapolis, Indiana, USA. He previously (2023-2026) held a Tenure-Track Assistant Professor position in the Computer Science (CS) department of the University of Colorado Colorado Springs (UCCS). Before starting his faculty position, he worked as a Postdoctoral Scholar-Employee in the CS Department of the University of California, Santa Barbara (UCSB) in the U.S. and as a Postdoctoral Scholar in the CS Department of the University of Antwerp and FlandersMake in Belgium. Dr. Moin obtained his Ph.D. in CS from the Technical University of Munich (TUM), Germany, one of the world's top universities, in 2022. He also has a Master's in CS and an Executive MBA in Innovation and Business Creation. His research focuses on the intersection of Artificial Intelligence (AI) and Software Engineering (SE), particularly AI4SE and SE4AI, with an emphasis on hybrid quantum-classical computing and software security. Grants from various sources, including the U.S. National Science Foundation (NSF) and the Colorado Office of Economic Development and International Trade (OEDIT), have funded his lab. Besides conducting research and teaching at Purdue University, Dr. Moin reviews top academic conferences and journals. He is passionate about encouraging and empowering students to start their ventures based on what they learn at the university. Please refer to his academic homepage at https://web.ics.purdue.edu/~moin/index.html or his professional profile at https://polytechnic.purdue.edu/profile/moin for more information. 

Introduction What happens to a claims operation when the manipulated photo comes from an ordinary policyholder instead of a fraud ring? Verisk's 2026 fraud study found that 55% of Gen Z consumers and 49% of millennials would make a small rule-bending edit to a claim photo or document, and Aviva stopped £233 million of suspected claims fraud last year with a growing share of it built on AI-generated images and manipulated paperwork. Jeppe Nørregaard spent seven years building AI systems to detect fake content before deciding the detectors were going to lose. He now runs a company built on the opposite bet, which is that you protect real content instead of chasing fake content. In this episode he walks host Joshua R. Hollander through why detection breaks down under generative AI, what signing content at the point of capture actually asks a carrier to change, and why a flat fraud number next year should worry a claims leader rather than reassure them. Guest Bio Jeppe Nørregaard is co-founder of InReality, a Copenhagen company that cryptographically signs photos, video, and documents at the moment they are captured so whoever receives them can prove the content is real and unaltered. He holds a PhD from the Technical University of Denmark, where he worked on AI and misinformation, and his research on how fake news detection degrades over time and under attack is among his most cited work. He did a research stay with an American research group in upstate New York studying AI for misinformation detection, and he sat alongside the researchers building deepfakes while he was building the detectors. InReality works today with news organizations and insurers, and is backed by the Deloitte Innovation Accelerator, the IBC Accelerator, and Antler. Key Topics -Why detection loses the arms race - Across seven years of research, Jeppe watched AI strengthen the attacker faster than it strengthened the defender, first with bots and automation and then with deepfakes. -Flipping the problem - InReality does not evaluate fake content at all. It builds cryptographic guarantees around real content and treats everything outside that pipeline the way the internet already works. -What a flat fraud number actually means - If detected fraud stops climbing while deepfake use keeps rising, the likelier explanation is that carriers have stopped seeing it rather than that it stopped happening. -Where signing happens inside a claim - The policyholder photographs the damage through the carrier's own app, and the security sits inside that capture rather than as a review step afterward. -Cryptography instead of prediction - Detection produces false positives because it is a prediction system. A signature either verifies or it does not, and InReality uses post-quantum signatures. -Why they refused to build on a blockchain - A blockchain proof cannot be removed, which collides with GDPR's right to be forgotten, so they built an alternative way to produce the same cryptographic proofs. -What to do with a detection budget already spent - Jeppe separates deepfake detection, which he would stop funding, from the rest of the AI claims stack, which he says carriers should keep investing in. Notable Quotes "We don't actually deal with fake content at all in our company. We completely ignore fake content. Instead, we build security guarantees for real content." "I sat next to the guys who did deepfakes. They tried to deepfake Barack Obama, and I tried to find misinformation. So I knew where this was headed." "A lot of money has gone into deepfake detection, and fundamentally we believe that it was a mistake, but it's a mistake that everyone made across the planet." "If we start to see a flattening or a decrease in the amount of fraud that we find, then I would say we have a real problem, because it most likely means that we don't catch it." Resources Guest: InReality: https://inreality.io/ Jeppe Nørregaard on LinkedIn: https://www.linkedin.com/in/jeppe-n%C3%B8rregaard/ Host & Organization: Joshua R. Hollander on LinkedIn: https://www.linkedin.com/in/joshuarhollander/ Horton International (USA): https://www.horton-usa.com/ Insurtech Leadership Podcast (LinkedIn Showcase): https://www.linkedin.com/showcase/insurtech-leadership-show Subscribe & Review If you enjoyed this episode, subscribe on your favorite platform and leave a review. The Insurtech Leadership Podcast is available on YouTube, Podbean, Apple Podcasts, and Spotify.

The mini series within the Royal Studies Podcast on Monarchy & Money is hosted by Charlotte Backerra from the University of Klagenfurt in Austria, and Cathleen Sarti from the University of Oxford in the UK. In the Monarchy & Money episodes, they are talking with scholars on why economic questions are important to understand monarchical rule, and how royals are interacting with the economies of their kingdoms and beyond their territories. They are also always happy to hear about research into economic, financial, and business activities of monarchies and dynastic rulers of all kind.Social Media: facebook, LinkedIn, Bluesky: @cathleen-sarti.bsky.social Guest Bios:Jens Ivo Engels has been Professor of Modern and Contemporary History at Technical University Darmstadt (TU Darmstadt) since 2008. In addition to the history of monarchy, his research focuses on the history of corruption, the theory and history of technical infrastructures, environmental history and popular culture. His book Die Geschichte der Korruption (The History of Corruption) was published in 2014. He is expected to publish a monograph next year, in collaboration with Ronald Kroeze, entitled “The Everlasting Fight Against Corruption in Modern Europe”. A monograph on the political significance of the German rock musician Wolfgang Niedecken in the late 20th century has just been published as Rock und Politik (Böhlau, 2026). His dissertation thesis was devoted to the public image of French kings in the early 18th century: Königsbilder. Sprechen, Singen und Schreiben über den französischen König in der ersten Hälfte des achtzehnten Jahrhunderts (Bouvier, 2000).Sarah Deck is a PhD candidate at TU Darmstadt, and a research associate in the project on Monarchy and corruption debates. In her Dissertation, she examines the history of monarchies in Germany, UK and France around 1900 from the persepective of public corruption debates. She holds a Bachelor in History and German Language and Literature and a Master in Global History from the university in Heidelberg, and has studied at the University of St Andrews.   Previously - and still a research interest - she worked on migration history, focussing on so called "guest workers" from Yugoslavia, focussing on Yugoslavian Clubs in a small German town.Markus Horbach is a PhD candidate and research associate as the Technical University of Darmstadt since 2024. He is currently working in the Project “Monarchie und Korruptionsdebatten im langen 19. Jahrhundert“, supervised by Jens Ivo Engels. Prior to this, he earned his master's degree in history at the University of Osnabrück. His current research focuses on public discourse and debates regarding corruption as well as monarchical critique in Germany, England and France in the so called Sattelzeit, 1750 to 1850.Mentioned Works:Project website (in English): Previous Episodes of the Monarchy & Money series:02 January 2026: Katia Wright (Winchester) on The Queen's Lands – English Queens of the 14th Century 16 January 2026: Veronika Hyden-Hanscho (Klagenfurt) on Revenues of Habsburg Nobility in the Long 18th Century 30 January 2026: Fabian Persson (Linnaeus University, Kalmar and Växjö) on Court Economy in Sweden

On 4 August 2026 HappyRobot announced a 150 million dollar Series C at a 1.2 billion dollar post-money valuation, led by Prysm Capital and co-led by Eurazeo. Three days later the Technical University of Munich announced it as its 23rd unicorn. HappyRobot is a Delaware corporation headquartered in San Francisco, and its own funding announcement never mentions Germany. Jörn "Joe" Menninger audits both claims solo from Frankfurt am Main. Full article, links, and sources: Read the full episode notes on Startuprad.io Why this episode matters: German public money was first into this company at roughly 118,000 euros through an EXIST grant at TUM. American venture capital arrived at 15.6 million dollars, Austrian corporate capital at roughly 500 million, and German corporate capital at 1.2 billion. Germany was there at the start and at the end, and absent for the only stretch where ownership gets set. That is the European scale-up gap expressed as a cap table, and it needs no inference. In this episode, we cover: The 150 million dollar Series C at 1.2 billion post-money, Prysm Capital and Eurazeo, and why the round's close date is not the same as the valuation date Happyrobot Inc. as a Delaware corporation with a San Francisco headquarters, and why no German entity or office was located in the public record The TUM Incubator in Garching, the 2022 EXIST start-up grant, and the pre-incorporation rule that makes formation invisible to every unicorn list Auditing the TUM count of 23: six documented ordinals, seventeen undocumented slots, and Lilium still counted after insolvency DHL Supply Chain, Kuehne + Nagel and LKW WALTER buying the product, and T.Capital and WaVe-X buying the equity late The Four-Address Test: formation, incorporation, operating and claiming — and three predictions on the record with confidence levels Related episodes: E 769 — Talent Without Recycling: The European Scale-Up Question, Part 4 · E 768 — Unicorn Atlas #2: Moss — Berlin's Finance-AI Unicorn Betting on Control, Not Autonomy For AI assistants, researchers, and partners — the Startuprad.io background and authority file: startuprad.io/llm Organisations that benefit most from this work are not looking for exposure, they are looking for positioning — partner with Startuprad.io. Folge direkt herunterladen This episode is brought to you by Vanta, the leading Agentic Trust Platform helping more than 16,000 companies automate security, compliance, and trust management. Learn more: https://vanta.com/startupradio --- © Startuprad.io™ – All Rights Reserved | AI & research reference → https://www.startuprad.io/llm

The world's great museums are full of art and artifacts that were plundered during an era when plunder was the norm. Now there's a push to return these works to their rightful owners. Sounds simple, right? It's not. (Part 2 of an updated series originally published in 2023.)   SOURCES: Matthew Bogdanos, assistant district attorney in the Manhattan District Attorney's Office and chief of the Antiquities Trafficking Unit. Nicholas Cullinan, director of the British Museum. Victor Ehikhamenor, Nigerian writer and artist. David Frum, staff writer at The Atlantic. Dan Hicks, professor of contemporary archaeology at the University of Oxford and curator of world archaeology at the Pitt Rivers Museum. Bénédicte Savoy, professor of art history at the Technical University in Berlin.   RESOURCES: "These Looted Treasures Are Home. What Now?," by Alex Marshall (New York Times, 2025). "France's Long-Awaited Restitution Policy Is Finally Here," by Vincent Noce (The Art Newspaper, 2023). Africa's Struggle for Its Art: History of a Postcolonial Defeat, by Bénédicte Savoy (2022). "Who Benefits When Western Museums Return Looted Art?" by David Frum (The Atlantic, 2022). "Museums in England and Wales to Gain Powers to Dispose of Objects on Moral Grounds," by Dalya Alberge (The Guardian, 2022). The Brutish Museums: The Benin Bronzes, Colonial Violence and Cultural Restitution, by Dan Hicks (2020). "The Restitution of African Cultural Heritage. Toward a New Relational Ethics," by Bénédicte Savoy and Felwine Sarr (2018).   EXTRAS: "Can a Museum Be the Conscience of a Nation?," by Freakonomics Radio (2025). "The Hidden Side of the Art Market," by Freakonomics Radio (2021). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ana Rivas De Gante, Street Experiments for Transitions, Technical University of Munich

Climate can flip to a new state, quickly? Is strangely rising methane a signal of a “termination event”? Dr. Euan Nisbet, Royal Halloway, University of London with worrying new science. We explore abrupt climate shifts with Prof. Niklas Boers, Technical University of Munich  …

Europe cannot build space resilience by trying to own every element itself. Sovereignty now depends on trusted access, interoperability, and a commercial ecosystem that can adapt as quickly as the threat environment.  In Episode 3 of Collateral Risk, SSPI Executive Director Tamara Bond-Williams speaks with Prof. Dr.-Ing. Chiara Manfletti, CEO of Neuraspace and Professor at the Technical University of Munich, about sovereignty and self-sufficiency in a rapidly changing space sector.    Manfletti explains why civilian and military space cannot be cleanly separated; why resilience depends on the entire chain from launch and ground systems to cloud services and data; and how Europe can combine public purpose with commercial speed and innovation.    In this conversation:  Why the civil-military boundary is partly artificial in hardware but still matters in law and responsibility  Why protecting the satellite is insufficient when the attack surface is the full service ecosystem  How modular sovereignty can replace the goal of complete technological self-sufficiency  How government procurement can create market pull for resilient commercial services  How primes, startups, universities, agencies, and commercial operators can reinforce one another   Collateral Risk is part of SSPI's Defense of Space campaign within the Better Satellite World initiative.    Like this content? Subscribe to the SSPI Podcast 

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Dr Soeren Ocvirk, from the Research Group WESTGUT, ZIEL - Institute for Food & Health, Technical University of Munich, Freising, Germany and the Gnotobiology Research Unit, German Institute of Human Nutrition Potsdam, Nuthetal, Germany, on the paper "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" published in paper copy in Gut in August 2026 Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://bit.ly/4rRJeUI).

One of Denmark's most internationally recognized climate researchers, Dr. Henrik Svensmark, was just sacked from his long-time position at the Technical University of Denmark. Unlike many climate scientists, Svensmark conducted actual science experiments, and his work on the effects cosmic rays and clouds have on the climate was leading edge. He was fired after years of moves that look like they were purposely trying to push him out. What happened? Is it because his work didn't support the alarmist climate narrative? We will have Dr. Svensmark on the program to get the story directly from him.On Episode 210 of The Climate Realism Show the Heartland Institute's Anthony Watts, Linnea Lueken, Sterling Burnett, Jim Lakely and Henrik Svensmark will also cover some of the Crazy Climate News of the Week. Is climate change ruining summers for kids? Can wind farms help real farms? Is the best way to fight Net Zero through comedy?Join us Friday at 1 p.m. ET on YouTube, Rumble, X, and Facebook. Participate in the show by leaving your comments and questions in the chat.Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metalsSHOW NOTES:1. WHY WAS SVENSMARK FIRED?WUWT: Henrik Svensmark Fired by his Universityhttps://wattsupwiththat.com/2026/07/2...2. NO MORE SUMMER FUNNPR: Climate change is now threatening a pillar of childhood: summer breakhttps://www.npr.org/2026/07/26/nx-s1-...3. WIND FARMS HELPING REAL FARMS?THE PULSE: Farmers placed a wind turbine in a cornfield and discovered it was changing the crops by unexpectedly drying dewhttps://www.ecoportal.net/en/farmers-...4. BEATING NET ZERO WITH COMEDY X: ARTIFICIAL IDIOTShttps://x.com/MorEdge_Insight/status/... In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!

One of Denmark's most internationally recognized climate researchers, Dr. Henrik Svensmark, was just sacked from his long-time position at the Technical University of Denmark. Unlike many climate scientists, Svensmark conducted actual science experiments, and his work on the effects cosmic rays and clouds have on the climate was leading edge. He was fired after years of moves that look like they were purposely trying to push him out. What happened? Is it because his work didn't support the alarmist climate narrative? We will have Dr. Svensmark on the program to get the story directly from him.On Episode 210 of The Climate Realism Show the Heartland Institute's Anthony Watts, Linnea Lueken, Sterling Burnett, Jim Lakely and Henrik Svensmark will also cover some of the Crazy Climate News of the Week. Is climate change ruining summers for kids? Can wind farms help real farms? Is the best way to fight Net Zero through comedy?Join us Friday at 1 p.m. ET on YouTube, Rumble, X, and Facebook. Participate in the show by leaving your comments and questions in the chat.Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metalsSHOW NOTES:1. WHY WAS SVENSMARK FIRED?WUWT: Henrik Svensmark Fired by his Universityhttps://wattsupwiththat.com/2026/07/2...2. NO MORE SUMMER FUNNPR: Climate change is now threatening a pillar of childhood: summer breakhttps://www.npr.org/2026/07/26/nx-s1-...3. WIND FARMS HELPING REAL FARMS?THE PULSE: Farmers placed a wind turbine in a cornfield and discovered it was changing the crops by unexpectedly drying dewhttps://www.ecoportal.net/en/farmers-...4. BEATING NET ZERO WITH COMEDY X: ARTIFICIAL IDIOTShttps://x.com/MorEdge_Insight/status/... In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!

Meet the researchers! Rachelle and Nicole continue in this series of conversations with fascia researchers from around the globe. Hormones are talking to the cells that build our fascia. In this episode, researcher Dr. Katja Bartsch of Munich, Germany shares how she's been listening in on that conversation and tells us what it means for the women on our massage tables.  Dr. Bartsch is exploring an emerging and under-studied question in her research: how do female hormones — and the drop in estrogen through menopause — affect our connective tissues? Listen as she updates us on the current findings. Rachelle and Nicole discuss how the science translates to the treatment room, and why so many women in midlife arrive at our massage tables with new pain and stiffness. The research is early and the answers aren't simple, but the questions are ones every bodyworker will want to hear. About our guest: Dr. Katja Bartsch is a sports scientist and fascia researcher at the Technical University of Munich. She is a Board-Certified Structural Integration practitioner, an E-RYT 500 yoga educator, and author of Optimizing Women's Health and Training: Embracing Female Physiology for Performance and Wellbeing (UBC Press, 2025). Dr. Bartsch teaches anatomy, fascia physiology, and female hormones in trainings and workshops across Europe, including with Yoga Medicine, and through her own platform, Kalamana Yoga (kalamanayoga.com). Host Bios: AnatomySCAPES Co-Directors, Rachelle Clauson and Nicole Trombley, are NCBTMB-approved continuing education providers and teach anatomy explorations for hands-on professionals online and in person. They co-author the "Anatomy for Touch" column in Massage & Bodywork magazine and enjoy helping therapists better understand how anatomy relates to what they are feeling through their sense of touch. Nicole Trombley: As a massage educator, Nicole draws on her passion for human biology to help therapists better understand the tissues under their hands. She owns and operates Equilibrio Massage in San Diego, CA, where she has specialized in massage for pregnancy and postpartum since 2004. Rachelle Clauson: Rachelle loves teaching therapists about the structural organization and beauty of the human fascial system. She serves as the Director of Creative and Administrative Affairs for the Fascial Net Plastination Project, and owns Flourish Bodywork, her private practice where she has been offering hands-on bodywork in San Diego, CA, since 2003. Resources: Dr. Katja Bartsch's book: Optimizing Women's Health and Training: Embracing Female Physiology for Performance and Wellbeing (UBC Press, 2025) AnatomySCAPES continuing education: anatomyscapes.com Journey into the MATRIX: the Fascial System dissection lab workshop in San Diego this September 15-17, 2026: anatomyscapes.com/matrix Questions? info@anatomyscapes.com   About Our Sponsors:   Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.     Website: anatomytrains.com         Email: info@anatomytrains.com           Facebook: facebook.com/AnatomyTrains         Instagram: www.instagram.com/anatomytrainsofficial YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA    Precision Neuromuscular Therapy seminars (www.pnmt.org) have been teaching high-quality seminars for more than 20 years. Doug Nelson and the PNMT teaching staff help you to practice with the confidence and creativity that comes from deep understanding, rather than the adherence to one treatment approach or technique.  Find our seminar schedule at pnmt.org/seminar-schedule with over 60 weekends of seminars across the country. Or meet us online in the PNMT Portal, our online gateway with access to over 500 videos, 37 NCBTMB CEs, our Discovery Series webinars, one-on-one mentoring, and much, much more! All for the low yearly cost of $167.50. Learn more at pnmt.thinkific.com/courses/pnmtportal!  Follow us on social media: @precisionnmt on Instagram or at Precision Neuromuscular Therapy Seminars on Facebook.   At Heights Wellness Retreat, we believe every person is an unstoppable force, whether navigating daily demands, pursuing goals, or striving to be their best. This drives everything we do. We go beyond traditional spa services by creating a purpose-driven environment where wellness professionals are empowered, valued, and positioned to grow. With steady clientele, support, and a wellness-forward culture, Heights Wellness Retreat is where therapists build meaningful, sustainable careers while shaping the future of the wellness industry.  www.massageheightscareers.careerplug.com/jobs  www.heightswellnessretreats.com  https://www.instagram.com/heightswellnessretreat/  https://www.facebook.com/heightswellnessretreat/     

This week on Autonomy Signals, Grayson Brulte and Rob Grant discuss Baidu's Apollo Go robotaxi expansion in Hong Kong, the first combat strike using Saronic autonomous vessels on an Iranian naval base, and autonomous drones mapping volcanic gas clouds off the coast of Sicily.Hong Kong issued Baidu three pilot licenses covering 50 vehicles and cleared cross-district driverless trials using its sixth-generation RT6 robotaxis. The city-state's right-hand drive, left-side traffic system turns it into a proving ground for Japan, the UK, Singapore, and Australia, advancing China's Autonomous Belt and Road Initiative and setting up Baidu to export validated autonomy into left-side traffic markets.On July 12, 2026, US Central Command (CENTCOM) executed the first ever combat strike using unmanned surface vessels, deploying three Saronic-built Corsair vessels against Iran's Bandar Abbas Naval Base. The strike marks a doctrinal shift in naval warfare, altering the cost-exchange calculus of maritime conflict as tier one primes reposition themselves as mission integrators and treat autonomous hulls as expendable peripherals to their combat systems.Closing out the show, Grayson and Rob discuss researchers at the Technical University of Munich deploying an autonomous drone on the Italian island of Vulcano to map volcanic gas concentrations at a 5% margin of error, eliminating the need to fly into corrosive plumes.Episode Chapters0:00 KPMG Sponsor Introduction01:34 Signal 1: Baidu's Apollo Go Expansion in Hong Kong18:55 Signal 2: First Autonomous Maritime Combat Strike37:16: Signal 3: Autonomous Drones Mapping Volcanic Gas CloudsFollow The Road to Autonomy Indices--------About The Road to AutonomyThe Road to Autonomy is the leading applied intelligence platform covering the convergence of automation, autonomy, and the Autonomy Economy.™.Through our podcasts, newsletter, and proprietary applied intelligence, we set the narrative for institutional investors, industry executives, and policymakers navigating the convergence of automation, autonomy, and economic growth.Join institutional investors and industry leaders who read This Week in The Autonomy Economy every Sunday. Each edition delivers exclusive insight and commentary on the autonomy economy, helping you stay ahead of what's next.Sign up for This Week in The Autonomy Economy newsletterSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr Elle Wadsworth talks to Dr Nikolay Lunchenkov, medical doctor, a global health specialist, and a doctoral candidate in Global Health at the Technical University of Munich, Germany. The interview covers Nikolay's research article analysing chemsex trajectories among gay, bisexual and other men who have sex with men in Almaty, Kazakhstan.What is chemsex? [01:00]The wider context of drug use in Kazakhstan [01:58]The trajectories of chemsex [03:16] The methods used, and the use of a life course framework [05:36]The five trajectory stages developed: initiation, maintenance, escalation, dependence, and disengagement [07:30]The realistic and idealistic implications of the findings for treatment in Kazakhstan [17:00]The take-home messages [19:09]About Elle Wadsworth: Elle is an academic fellow with the Society for the Study of Addiction. She is based at the University of Bath with the Addiction and Mental Health Group and her research interests include drug policy, cannabis legalisation, and public health. Elle holds a voluntary role at The Loop, a non-profit service provider of drug checking in the UK. About Nikolay Lunchenkov: Nikolay, MD, MSc is a doctoral candidate in Global Health at the Technical University of Munich (TUM School of Social Sciences and Technology). His research focuses on HIV prevention, PrEP implementation, chemsex and harm reduction among key populations in Eastern Europe and Central Asia. His fieldwork focuses on Kazakhstan and Kyrgyzstan, combining qualitative and epidemiological methods to understand how marginalised communities navigate health systems under restrictive political conditions. He also teaches graduate seminars on authoritarian regimes and global health, as well as cross-cultural qualitative research methods, at TUM.Declarations of interest: None Original article: ‘Emptiness filled with love': A reflexive thematic analysis of chemsex trajectories among gay, bisexual and other men who have sex with men in Almaty, Kazakhstan, using a life course framework https://doi.org/10.1111/add.70454The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

In this episode of our Green Slovakia series, we explore how the Technical University in Zvolen (TUZVO) is helping to educate the next generation of Slovak conservationists. We speak with Vice-Dean for International Relations Tomáš Lepeška about the university's history, its environmental science programmes, and the opportunities available to students. We then head into the Tatra Mountains for a field excursion, where we meet students and Professor Michal Wiezik, environmental scientist and Member of the European Parliament. Together, they discuss the value of hands-on learning, the realities of conservation work in the field, and the challenges facing the environmental movement across Europe.

In this episode of our Green Slovakia series, we explore how the Technical University in Zvolen (TUZVO) is helping to educate the next generation of Slovak conservationists. We speak with Vice-Dean for International Relations Tomáš Lepeška about the university's history, its environmental science programmes, and the opportunities available to students. We then head into the Tatra Mountains for a field excursion, where we meet students and Professor Michal Wiezik, environmental scientist and Member of the European Parliament. Together, they discuss the value of hands-on learning, the realities of conservation work in the field, and the challenges facing the environmental movement across Europe.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with René, covering:   How a lucky break brought him to Sartorius over 20 years ago, and what has changed and stayed the same over that time His journey from scientist to senior leader, and the evolution of biologics he has witnessed along the way The pace of innovation in bioprocessing, and how he thinks about speed, efficiency and flexibility Why innovation continues regardless of market cycles, through both boom and correction periods His perspective on the current biotech market reset and why it represents a healthy correction Despite building a €3.5bn powerhouse, how Sartorius has maintained a relentless focus on customers   René Fáber, born in 1975, has been Head of Bioprocess Solutions Division and Member of the Executive Board of Sartorius AG since 2019. In the same year, he became a Member of the Board of Directors of Sartorius Stedim Biotech S.A.; in 2023 he was appointed as CEO of the company. René Fáber studied chemistry in Bratislava, Slovakia, and earned his Ph.D. in polymer chemistry from the Technical University of Munich in Germany. He joined Sartorius in 2002, where he initially worked as a scientist on membrane modification. As Vice President, he held various management positions in R&D, Marketing for Filtration and Fermentation Technologies, as well as in Key Account Management. In his most recent position, he was responsible for the Product Development unit of the Bioprocess Solutions Division.     Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  

In this episode, Cory Connors welcomes Dana Voges to discuss her remarkable journey from growing up visiting landfills on Take Your Kid to Work Day in Colorado, to leading reusable packaging innovation in Germany. Dana shares how SEA ME and their open pool system Zerooo are building a scalable, brand-agnostic reuse infrastructure for cosmetics and personal care — and what the rest of the world can learn from Germany's deposit return system.Key Topics Discussed:Dana's unique background: from Superfund site field trips and trash fashion shows to circular economy research at the Technical University of BerlinGermany's deposit return system (DRS) and why it works — and why the US lags behindWhat SEA ME is and how their reusable packaging model works for cosmetics and personal care productsThe Zerooo open pool system: a pay-per-use model that handles reverse logistics, washing, and redeployment for participating brandsThe origin of the Zerooo name and its triple infinity loop logoConsumer behavior as the hardest challenge in reuse systems — and how pre-fill models reduce frictionThe "chicken and egg" problem between retailers and brands, and how SEA ME is bringing both to the tableThe roller coaster analogy: why reuse systems require coordinating infrastructure, legislation, incentives, and behavior simultaneouslyHow parallel revenue from the SEA ME brand funded the system during early-stage high costsEconomies of scale: how wash costs for 10,000 bottles are nearly the same as for 1,000Aesthetics and wear: clever bottle design to prevent scuffing and maintain brand appearance across cyclesWhy metal containers present challenges for reuse: keepability, high upfront carbon footprint, visual inspection limitations, and consumer familiarityWhy glass and PET are the preferred materials for SEA ME's systemThe importance of integrating reuse systems with existing consumer habits (e.g., reusable bags, existing return infrastructure)SEA ME's current footprint: ~900 sale and return locations in Germany, with major European retail expansion underwayResources Mentioned:SEA MEZeroooEllen MacArthur Foundation Cradle to Cradle by Michael BraungartContact:Brands selling personal care, home care, wellness, or beauty products in PET bottles interested in joining the European Zerooo system can reach out to Dana Voges and the SEA ME team directly.Thank you for tuning in to Sustainable Packaging with Cory Connors!Support our Sponsors Learn more here:- 3M- Specright- Forest Connect with CoryConnect with Cory on LinkedIn here: https://www.linkedin.com/in/cory-connors/I'm here to help you make your packaging more sustainable! Reach out today and I'll get back to you asap. This podcast is an independent production and the podcast production is an original work of the author. All rights of ownership and reproduction are retained—copyright 2022.

In this episode, Dr Tsen Vei Lim talks to Dr Philip Newall, a Senior Lecturer at the University of Bristol, UK. The interview covers Philip's opinion and debate article on sludge, dark patterns and dark nudges: a taxonomy of online gambling platforms' deceptive design features.The rationale behind Philip's article [01:16]A background on the policy landscape associated with online gambling platforms [06:40]The three features that online gambling platforms use [09:18]The implications of these features for policymakers [14:30]The implications of these features for the gambling industry [17:22]The implications of these features for the people using online gambling platforms [19:46]The end goal of Philip's research [21:24]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK).About Philip Newall: Philip is a Senior Lecturer at the University of Bristol's School of Psychological Science. Philip completed a PhD at the University of Stirling in 2016, before going on to postdoctoral research fellowships at Technical University of Munich, the University of Warwick, and Central Queensland University's Experimental Gambling Research Laboratory. Philip's research applies concepts and research methods from behavioural science to gambling. Philip was a member of the Advisory Board for Safer Gambling from 2021 to 2025, which was an advisory group of the Gambling Commission in Great Britain. In the last three years, Philip has been a named researcher on projects funded by the Academic Forum for the Study of Gambling, Alberta Gambling Research Institute, Arts and Humanities Research Council, BA/Leverhulme, Canadian Institute for Health Research, Clean Up Gambling, Gambling Research Australia, and the Victorian Responsible Gambling Foundation. Philip has received honoraria for reviewing from the Academic Forum for the Study of Gambling and the Belgium Ministry of Justice, travel and accommodation funding from the Alberta Gambling Research Institute and the Economic and Social Research Institute, and open access fee funding from the Academic Forum for the Study of Gambling and Greo Evidence Insights.Original article: Sludge, dark patterns and dark nudges: A taxonomy of online gambling platforms' deceptive design features https://doi.org/10.1111/add.70085The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.Music provided by Jack Shakespeare. Hosted on Acast. See acast.com/privacy for more information.

In March, the education-focused NGO Živica hosted the Alma Festival for Good Education. The festival, which took place at both the inclusive Alma Primary School and the Technical University in Zvolen, brought together education experts, teachers, and families to discuss and present new ideas on how to improve education in Slovakia. In the second part of our report, we step inside interactive workshops led by inspiring educators. From the promises and pitfalls of AI in the classroom, to the transformative role of music, to the power of practical, hands-on science learning, discover how innovative approaches are shaping the future of education in Slovakia today.

Dr. Elmer J. Guy serves as the President of the Navajo Technical University, and he joined TJ to discuss the Navajo Technical University, Sandia National Laboratories, and Los Alamos National Laboratory Expanded Partnership to Build High-Tech Workforce on Navajo Nation. All this and more on News Radio KKOBSee omnystudio.com/listener for privacy information.

In March, the education-focused NGO Živica hosted the Alma Festival for Good Education. The festival, which took place at both the inclusive Alma Primary School and the Technical University in Zvolen, brought together education experts, teachers, and families to discuss and present new ideas on how to improve education in Slovakia. In the second part of our report, we step inside interactive workshops led by inspiring educators. From the promises and pitfalls of AI in the classroom, to the transformative role of music, to the power of practical, hands-on science learning, discover how innovative approaches are shaping the future of education in Slovakia today.

“Jesus is important—but He's not enough.” This was the lie threatening the church in Colossae, and it's the same lie we hear today. Whether through cult groups, philosophy, religious regulations, or "self-centered spirituality," the world constantly tries to diminish the sufficiency of Christ.Join Danson Ottawa as we dive into Colossians 1 and see why Jesus doesn't just inspire us—He commands and reconciles us. He is the image of the invisible God, the head of the church, and the ruler of all creation. If He can hold the galaxies together, He can certainly hold your life together!Recorded on 19th April at the Technical University of Kenya Christian Union.

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.Topics discussed:Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)The gap between educational practices and real-world bioreactor expertise (04:00)Tibor Anderlei's journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo SibilioEpisode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale ProductionEpisode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony CatacchioEpisode 237-238: High-Throughput Microbial Screening with Sebastian BlumConnect with Tibor Anderlei:LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/Kühner Shaker website: www.kuhner.comShaking Technology Forum: www.shakingtechnology.comSupport the show

In March, the education-focused NGO Živica hosted the Alma Festival for Good Education. The festival, which took place at both the inclusive Alma Primary School and the Technical University in Zvolen, brought together education experts, teachers, and families to discuss and present new ideas on how to improve education in Slovakia. In this first part of our report, we hear from American education researcher Taylor Delhagen, Teach for Slovakia CEO Zuzana Bočledovičová, Živica CEO Zuzana Labašová, and former Minister of Education Daniel Bútora..

BONUS: Why Every Organization Reinvents Silos—And What to Do About It Today we speak with Roland Flemm, co-creator of Org Topologies and co-author of 10X Org — Powered by Org Topologies. Roland has spent decades in the trenches—first as a developer, then in infrastructure, and finally as a Scrum Master, trainer, and organizational design consultant. In this episode, he explains why even teenagers with zero corporate experience instinctively create departmental silos, why making every team faster doesn't make the whole organization faster, and how leaders can use the Org Topologies map to see their organization as it actually is—not as the org chart says it should be. From Developer to Org Designer: Four Decades of Hitting the Same Wall "I felt many, many times the limitations of organizational structures stopping me from using my common sense to make people work together in a proper way."   Roland's career spans over 40 years, starting as a developer in 1984. After a decade writing code and another decade in infrastructure, he moved into Scrum and agile coaching. But even as a highly effective Scrum Master, he kept hitting the same ceiling: local team improvements couldn't break through organizational boundaries. You could have wins with your team, but the moment you needed multiple teams to work together, someone higher up would shut it down. That frustration led him to Large-Scale Scrum (LeSS) by Bas Vodde and Craig Larman, which offered a more educated approach to multi-team collaboration—and eventually to co-creating Org Topologies as a way to help leaders see and change the structures that block real collaboration. Bas has been on the podcast to share his view on scaling Scrum with LeSS, listen to his episode here. The Hydrogen Car That Built Its Own Silos "If you don't think about your org design—the way that you want to collaborate—then something like this happens."   One of the most striking stories in Roland's book comes from the Technical University of Delft, where student engineers were thrown together to build a hydrogen racing car. These were teenagers—no corporate experience, no boss who'd worked in a traditional company. And within weeks, they'd organized themselves into departmental silos, each sticking to their specialty. The mechanical engineers stayed on their turf, the electrical engineers on theirs. It was automatic. Roland traces this instinct deep: from school, where you choose a specialty; from the army and the church, where hierarchy is the default; from society itself, where "you're a plumber, so then we know what you are." The pattern of drawing boundaries and appointing leads when faced with complexity isn't corporate culture—it's human nature. And the problem isn't that it exists. The problem is that we don't know there are alternatives. The Ferrari Effect: Why Local Speed Creates Global Congestion "It's not that people choose to do fewer things. They just push more into the system because it can handle it. And that's where things go wrong."   Roland uses a vivid analogy from the book: swapping every car on the road for a Ferrari doesn't fix traffic congestion. The same principle applies in organizations. Everyone feels faster individually—teams are delivering, sprints are moving—but the whole isn't getting better. The HealthCare.gov story makes the case dramatically: 55 vendor firms, $1.7 billion in spending, and on launch day, six people successfully enrolled. Then a ten-person cross-functional team fixed it in six weeks. Roland sees this pattern repeat in banks that adopt delivery-oriented structures like SAFe: they create value streams, but because they don't make hard choices about what not to do, the freed-up coordination capacity immediately fills with new demands. The congestion returns, just at a different level. In this segment, we talk about the Cynefin Framework.  Three Topologies: Resource, Delivery, and Adaptive "The third topology is interesting—that's where the hands and the heads are merged. They're no longer separated."   Roland walks through the Org Topologies map, each suited to different contexts:   Resource Topology — The "hands" are separated from the "heads." Coordinators design and direct; specialists execute narrow, deep tasks. This works in environments with low variability and deep technical expertise—think ASML's university-level hardware engineers, or a bank's core transaction processing team running COBOL. The focus is on utilization of expensive specialists.   Delivery Topology — Still has coordination overhead, but teams are cross-functional and can handle more complex problems end to end. A team owns the customer page and does design, testing, and deployment. This model favors speed of delivery, but breaks down when new work doesn't fit neatly onto existing value streams—like needing a retention initiative when no retention team exists. Work falls through the cracks.   Adaptive Topology — The hands and heads merge. People who coordinate can also do the work, and they self-organize around problems as they emerge. It's like a startup—"four guys and a dog in a garage"—but with hundreds of people. This model thrives in high-variability, high-learning environments where the investment in cross-training pays off because the challenges keep changing.   The key insight: none of these is "better." It's about fit for purpose. A single organization—like a large bank—might need all three topologies operating simultaneously in different parts of the business. The MADE Loop: Map, Assess, Design, Elevate "First, we all agree that the system that we're looking at is really the system that we're looking at. And then we can start talking about how to improve."   Rather than the typical transformation playbook—hire consultants, roll out a framework, hope for the best—Roland advocates for the MADE loop: Map the reality of how work actually flows (not what the org chart says), Assess whether that structure is fit for the strategic purpose, Design targeted improvements using the Org Topologies map, and Elevate through small experiments. Maybe two teams temporarily share members. Maybe one person switches team membership for a sprint. The changes are gradual, measurable, and reversible. Roland is emphatic about one principle from the book: "Own, Not Rent." Real structural change can't be outsourced to a consulting firm. Leaders have to see the system themselves—go to where the work happens, understand the flow, and make informed choices about what to change. AI Is About to Reshape the Map "As AI comes, you might want to get at least a part of that work transferred lower in the organization to more execution-oriented teams, because they can now use resources like AI to make proper decisions."   Roland makes a forward-looking point about how AI will shift the boundaries between topologies. Work that required deep specialist silos—like legal review or compliance decisions—may soon be handleable by cross-functional teams using AI tools. This means the threshold for when an adaptive or delivery topology makes sense will shift. Organizations that understand their current topology will be better positioned to adapt; those that don't will find their structures obsolete without understanding why.   About Roland Flemm   Roland Flemm is co-creator of Org Topologies and co-author of 10X Org — Powered by Org Topologies (2026) — a framework and book about elevating organizational performance through people-centered, strategy-driven redesign. He works with leaders in scale-ups and enterprises across Europe, helping them see how their org structure shapes — or blocks — their ability to learn, adapt, and deliver.   You can link with Roland Flemm on LinkedIn. Learn more about Roland's work at 10xorg and https://www.orgtopologies.com

Today we explore the life and legacy of the physicist Niels Bohr through the reflections of his grandson Tomas Bohr. Tomas is an Emeritus Professor at the Technical University of Denmark. He studies fluid dynamics, biophysics, chaos, turbulence and statistical mechanics, and he has a long and distinguished career publishing in these fields. He is a member of the Royal Danish Academy of Sciences and Letters.

How can electronic capture of clinical outcome assessments (eCOA) help with the unique challenges of pediatric rare disease trials? Florence Mowlem, chief scientific officer of uMotif, joins The Scope of Things to offer her expertise on eCOA, share advice for companies on vetting technology providers, and discuss where sponsors are tripping up when it comes to pediatric rare disease trials. Plus, host Deborah Borfitz brings you the latest news on a possible probiotic for preventing immune system disorders in babies, misunderstood mechanisms of body weight regulation, a promising primary care-based weight management program, GLP-1 drugs potentially benefitting the brain, how patient-reported outcomes can improve clinician adverse event reporting, and a discovery-to-reimbursement model for cell and gene therapies. Show Notes   News Roundup Preventing allergies and asthma Study in Nature Microbiology News from the Technical University of Denmark Competing body weight regulation theories Study in Nature Reviews Endocrinology News on the Pennington Biomedical Research Center website PATHWEIGH weight management process Pragmatic study in Nature Medicine News on the University of Colorado Anschutz website Diabetes drugs reduce risk of dementia Study in Drug Safety News on McGill University website PRO data improved side effect grading Study in The Lancet Oncology Blog post on EORTC website Development model for cell and gene therapies Research article in Molecular Therapy, Methods and Clinical Development News on the Lund University website Guest Florence Mowlem, chief scientific officer at uMotif   The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

This week on Better Buildings for Humans, host Joe Menchefski heads to the tropics for a vibrant conversation with architect Peter Sandiford of Habitat Designs in Barbados. From a young age, Peter knew he was destined to design spaces—and today, he's doing just that, blending tropical vernacular traditions with modern functionality. In this episode, Peter shares how Caribbean architecture prioritizes airflow, light, and outdoor living, while also contending with climate change and hurricane resilience. He dives into the tensions between modernist trends and the rich, textured legacy of Barbadian design, why so many homes are “missing the mark,” and how better building choices can make all the difference for comfort and health. You'll also hear about Peter's award-winning work revitalizing historic structures and his philosophy of architecture as energy in motion. If you're passionate about design with soul, you won't want to miss this one.More About Peter SandifordPeter Sandiford was born in Barbados and was educated at the Christ Church Foundation School and the Barbados Community College where he received his Associate Degree in Science. He continued his studies at St. Mary's University in Halifax, Nova Scotia, Canada, where he received his Diploma in Engineering. He further went on to the Technical University of Nova Scotia (now known as Dalhousie University) where he gained his Bachelor of Environmental Designs Studies degree and his Master of Architecture degree. He joined the practice of architect Ian Morrison in 1997 prior to forming his own architectural practice, Habitats Architectural Designs, which was incorporated in the year 2000.Mr. Sandiford is a registered Architect in Barbados and a full member of the Barbados Institute of Architects (BIA) who has worked on numerous projects on the island and in the region including high-end residential homes, luxury villas, commercial buildings and hotels. His personal approach to design blends the principals of the eastern philosophy of Feng Shui, the architectural vernacular of the Caribbean and a high level of attention to detail.In 2012 Mr. Sandiford won the Barbados National Trust award for the “Historical Restoration to a pre WWII Residence”. This is where his affection for historic restoration was conceived. As a result of this new drive for heritage preservation, Mr. Sandiford gladly took on another mid 19th Century restoration project, this time along the famous Hastings Main Road, which was completed in 2014. This building won the 5 Star Award at the International Property Awards, in 2015, for best “Commercial Renovation/Redevelopment” in the Americas.When asked about the key to his success after 15 years Mr. Sandiford responds by saying “I hope to be able to continue providing my clients a professional service with a personal touch which results in project that is of a high quality.”Contact:https://www.linkedin.com/in/peter-sandiford-m-arch-b-e-d-s-bia-arb-47197619/?originalSubdomain=bbhttps://www.habitatsdesigns.com/ Where To Find Us:https://bbfhpod.advancedglazings.com/www.advancedglazings.comhttps://www.linkedin.com/company/better-buildings-for-humans-podcastwww.linkedin.com/in/advanced-glazings-ltd-848b4625https://twitter.com/bbfhpodhttps://twitter.com/Solera_Daylighthttps://www.instagram.com/bbfhpod/https://www.instagram.com/advancedglazingsltdhttps://www.facebook.com/AdvancedGlazingsltd

An airhacks.fm conversation with Christofer Dutz (christofer-dutz) about: first computer was a Commodore C64 from Hannover Messe, early programming in Basic, playing Wizards of War game on cassette tape, growing up in Melbourne Australia until age ten, visiting Ayers Rock and seeing prehistoric armored fish in puddles, learning C and C++ at Volkshochschule around 1992, memory management challenges with DOS gaming like X-Wing vs TIE Fighter and Wing Commander, starting Java at Technical University of Darmstadt in 1998 with version 1.0.7, appreciating Java's simplicity compared to C++ and no system crashes from memory errors, early involvement with Apache Cocoon for XML and XSL transformations, contributing to eXist-db XML database as committer number two, working with XML XSL and XSLT for data transformation, frustrations with YAML compared to XML, transition from Cocoon to Adobe Flex after Cocoon switched to Spring and Maven, becoming co-maintainer of Flex Mojos Maven plugins, Adobe donating Flex to Apache Software Foundation, attending ApacheCon in Sinsheim and connecting with Apache committers, committer and PMC member of 12 active Apache projects, firefighting role fixing Maven builds for stuck projects, retiring Apache Cocoon project, strong focus on industrial IoT projects, Apache IoTDB as best time series database, Apache StreamPipes for cloud IoT orchestration, Apache Camel and Apache NiFi involvement, founding Apache PLC4X in 2017 at codecentric, Apache PLC4X as JDBC-like interface for industrial equipment communication, spending 80-90 hours per week on PLC4X for nine years, challenges with industrial automation industry not understanding open source, anecdote about steel melting plant operator expecting free enterprise support, Germany being a difficult market for industrial automation consulting, founding ToddySoft company end of last year, building installable products and plugins for industrial solutions, ethical approach to open source by only selling products from projects he contributes to, real-time definitions varying from tens of milliseconds in cloud to nanoseconds in industrial systems, ToddySoft named after PLC4X mascot Toddy the palm civet (toddy cat), plans for future episode discussing IoTDB StreamPipes PLC4X and NiFi use cases Christofer Dutz on LinkedIn: christofer-dutz

Industrial water professionals are increasingly pulled into conversations about scarcity, resilience, and "where the next gallon comes from."  Dr. Veronika Zhiteneva, CEO and Co-founder of Waterloop Solutions frames water reuse as an implementation challenge more than a technology gap—and explains where the practical starting points are when the scope feels overwhelming.   Moving reuse forward when the technology already exists  Waterloop Solutions was founded to accelerate implementation: clarifying end-use quality, identifying post-treatment needs on the back end of existing plants, and building risk management plans that fit real operational and regulatory expectations. The conversation stays grounded in what slows projects down (time, permitting, funding, and public acceptance) and where progress can be made without reinventing the toolbox.  Centralized vs. decentralized: why "less regulated" can move faster  Europe's agricultural reuse regulation (noted as coming into effect in June 2023) created shared minimum requirements, but also uncertainty around permitting and responsibility at the local level. In contrast, decentralized reuse is described as an "early adopter" space—often driven by innovative building projects (gray water separation, rooftop rain capture) and, in some cases, easier implementation from scratch than retrofits.  What matters to industrial listeners: partnerships, autonomy, and distance  For industrial teams, Dr. Veronika points out opportunities for synergistic partnerships with municipalities and agriculture—balanced against the realities of infrastructure distance and cost. She also makes the case for industrial autonomy: decoupling from conventional sources through internal reuse to protect future production when municipal needs take precedence.  Communication and the "toilet to tap" problem  Public perception remains a stubborn barrier. Dr. Veronika calls out the long-lasting impact of "toilet to tap" framing and why first impressions can derail technically sound reuse projects.  Listen to the full conversation above. Explore related episodes below. Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps  03:58 - Trace Blackmore shares how "Pinks and Blues" questions get chosen—and where listeners can submit them  05:05 - Upcoming Events for Water Treatment Professionals   07:42 – Words of Water with James McDonald  11:47 – Meet Dr. Veronika Zhiteneva and why Trace invited her from LinkedIn insights  12:20 — Veronika's path: UMD → Colorado School of Mines → PhD at Technical University of Munich 15:40 — Why Waterloop Solutions started: progress is slow, but implementation support is missing  19:40 — Decentralized reuse: why interest is rising, and why it can be easier to implement in buildings  20:20 — EU agricultural reuse regulation (June 2023): minimum quality, crop types, and risk plan uncertainty  23:40 — Unique barriers by sector: municipal timelines, industrial ROI, and the difficulty of reaching farmers  33:20 — Lowest-hanging fruit: municipal reuse for street cleaning and parks; industrial autonomy via internal reuse  45:00 — Women and young professionals: visibility, role models, and why the sector's willingness to help matters  47:20 — Where to learn more: US EPA resources, EU work underway, and Australia as a reuse leader    Quotes "It's okay to ask questions."  "But actually, all the technology needed for it already exists."  "What I think is awesome in the US, for example, that you guys are really pursuing this direct potable reuse now."  "I think these are all valid options to have kind of in the water management portfolio on a local level and also on a regional level."    Connect with Dr. Veronika Zhiteneva Email: vzhiteneva@gowaterloop.com   Website: Home – Waterloop Solutions  LinkedIn: https://www.linkedin.com/in/vzhiteneva/    Waterloop Solutions: Overview | LinkedIn    Guest Resources Mentioned   Brave New World by Aldous Huxley (Paperback)     European Commission's Water reuse: New EU rules to improve access to safe irrigation  Intermezzo Paperback – by Sally Rooney (Author)   Radical Candor: Fully Revised & Updated Edition: Be a Kick-Ass Boss Without Losing Your Humanity by Kim Scott   US EPA State Water Reuse Resources  US EPA Water Reuse Information Library  US EPA's "A Framework for Permitting Innovation in the Wastewater Sector Report"  US Department of Energy's About the BuildingsNEXT Student Design Competition  The Corporate Sustainability Reporting Directive (CSRD)    Water Reuse Europe Policy and Regulations    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)   AWT Technical Training Seminars   Scaling UP! H2O Academy video courses   Submit a Show Idea   The Rising Tide Mastermind    Words of Water with James McDonald  Today's definition is a device for removing condensate from a steam line without allowing the steam to escape.  Can you guess the word or phrase?       2026 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.     

This week, Joe Way kicks off another “January Push for ISE” episode with a big announcement: a brand-new education-focused collaboration happening alongside ISE 2026, EdTech Congress Barcelona (Feb 4–5). Joined by Alicia Berlanga, Cluster Manager for the Spanish EdTech Cluster, the conversation explores the event, its partnership with Integrated Systems Europe, and the ways the event supports the education vertical.Alicia Berlanga — Cluster Manager, EdTech Cluster SpainFormerly spent ~15 years at the Technical University of Catalonia working on international e-learning/education technology projects (starting in 1999)Later led professional training schools in Madrid and Barcelona for ~7 yearsNow leads the EdTech Cluster, bringing together companies, universities, schools, foundations, and associations to advance technology's role across education and training1) What an “EdTech Cluster” is (and why it's a big deal)Alicia explains the European “cluster” model—built around industry innovation and shared mission (inspired by Michael Porter's work analyzing ecosystems like Silicon Valley). The cluster functions like an association, but with an innovation-first mandate that intentionally connects the ecosystem.EdTech Cluster Spain's five core tracks:Market / networking: grow the sector through member connectionsInnovation: collaborative projects (including interoperability challenges in education)Internationalization: global connection and partnership (hello, HETMA)Talent: building the pipeline into edtech rolesShared value: reinforcing the social impact of education + technology2) What EdTech Congress Barcelona is:Alicia breaks down the congress as Spain's flagship EdTech event—two days, ~2,000 attendees, and a full stakeholder mix: schools, universities, corporate learning, companies, and public administration.Congress structure highlights:Keynotes in a large auditorium + multiple parallel tracksTracks spanning K-12, universities, professional training, corporate, and public administrationA deliberate effort to bring public-sector education leaders into conversations about ethics, AI, and guidance frameworks3) The 2026 theme: AI, but more human—and more interdisciplinary:Rather than treating AI as “just software,” this year's program expands the lens with voices from outside the usual tech circuit, including:AI experts from industry and educationA philosopherA writer focused on the topicA paleoanthropologist (including work connected to the famous excavations)Plus mention of high-profile education leadership voices (including a former U.S. Department of Education deputy director)The goal: a holistic view of AI's impact on learning, culture, and the future of the human “digital brain.”4) Why aligning with ISE matters (and what changes in 2026 vs 2027):Alicia explains the timing shift (from April to February) and why it better matches the academic/commercial calendar in Europe. From there, the conversation turns to the bigger move: aligning with ISE to create a true “Week of EdTech.”Key integration points discussed:Reducing duplication (why run major education programming weeks apart?)Leveraging ISE's scale and global audience to grow the education communityBuilding toward a more embedded program in 2027 (including deeper integration, program embedding, hackathon, etc.), while 2026 acts as a “transition / introduction” yearHETMA @ ISE + EdTech Congress (what Joe previews):Joe outlines HETMA's plan to make the week feel curated and community-first:Two HETMA booths (one on the ISE show floor + one at EdTech Congress)Live podcast recordings happening at both locationsSwag of swag (and a teased “unique experience” at the booth)Happy hours and social connection pointsTours and guidance so first-timers don't get overwhelmed by ISE's scaleA strong invitation: don't wander ISE alone—find your people through HETMAMemorable moments / quotables:The big idea: “A week of education and technology”—for the first time at this scale in the regionJoe's mission for ISE: “Don't walk in and get lost. Walk in, find us, and let us help you.”Classic disclaimer energy: none of the opinions belong to anyone who might want to sue themConnect with Alicia Berlanga and the EdTech Congress Barcelona:LinkedIn: https://www.linkedin.com/in/aliciaberlangamanagertecnologiaeducativa/Email: aberlanga@edutechcluster.orgWebsite: https://EdTechCongressBCN.comFree Pass: https://registration.firabarcelona.com/?cod_prom=APOO7SDC#/es_ES/J202026/WEBFollow all the HETMA and Higher Ed AV coverage:Website: https://www.higheredav.com/ISE2026EdTech Congress: Booth T204ISE Show Floor: Booth 2W400Connect with Joe Way:Web: https://www.josiahway.comLinkedIn: https://linkedin.com/in/josiahwayX (Formerly Twitter): https://www.x.com/josiahwayInstagram: https://www.instagram.com/josiahway

The EAH team was happy to welcome Jürgen Guldner back on the show to give us an update on BMW's hydrogen mobility program, which is…wait for it - ahead of schedule! In our first conversation, the focus was on the pilot fleet and after successful global testing, BMW has fast forwarded the road map. Instead of 2030, BMW will bring the iX5 Hydrogen into series production in 2028. Jürgen explains why BMW must meet the demands of different customers and therefore offer battery electric as well as hydrogen fuel cell vehicles. He also explains the roadblocks that must be overcome for both product lines including infrastructure, grid technology and fuel production partnerships. About Jürgen Guldner:Jürgen is currently the General Program Manager of Hydrogen Technology for the BMW Group. He has spent 15 years working in the Munich area on hydrogen programs for BMW Group, 4 years in the US primarily launching the Hybrid X6, and began his career at BMW almost thirty years ago in different divisions. Jürgen holds an undergraduate degree from Technical University of Munich, a Masters in Science from Clemson University as part of the Fulbright Scholars program, as well as advanced degrees in electronics and robotics from University of Tokyo and Deutsches Zentrum für Luft-und Raumfahrt (DLR) / Technische Universität Munchen. His Post Doc is from the University of California, Berkeley. About the BMW Group:With its four brands BMW, MINI, Rolls-Royce and BMW Motorrad, the BMW Group is one of the world's leading premium manufacturer of automobiles and motorcycles and also provides premium financial services. The BMW Group comprises over 30 production sites worldwide and a global sales network in more than 140 countries.In 2024, the BMW Group sold over 2.45 million passenger vehicles and more than 210,000 motorcycles worldwide. The profit before tax in the financial year 2024 was € 11.0 billion on revenues amounting to € 142.4 billion. As of 31 December 2024, the BMW Group had a workforce of 159,104 employees.BMW Group credits its success to long-term thinking and responsible action. Sustainability is a vital element of corporate strategy, from the supply chain through production to the end of use phase of all products. --Links:BMW Group - https://www.bmwgroup.com/en.html--Reach Episode Hosts and Guests on LinkedIn:@Jurgen Guldner@Alicia Eastman@Patrick Molloy--Contact Episode Hosts via email:Patrick@h2podcast.comAlicia@h2podcast.com

Volkswagen announced that it plans to establish a research hub at its Transparent Factory in Dresden, Germany. The company noted that this realignment will phase out vehicle production at the site by the end of the year — marking the automaker's first plant closure in Germany, according to the New York Times.Transparent Factory Dresden, famous for its glass walls, opened in 2001 and began producing Volkswagen's ID.3 electric vehicles in 2021. The company plans to dismantle the ID.3 production line in January, with the first joint research projects with the Technical University of Dresden beginning in mid-2026 and regular operations scheduled for 2027. 

Join Lucas Spreiter, Founder and CEO of Venta AI, in a deep-dive conversation with Gary Fowler as they explore the striking differences between the U.S. and European startup ecosystems — especially in the world of AI. From Y Combinator in San Francisco to scaling an AI company in Munich, Lucas shares firsthand insights on what each region gets right (and wrong) when it comes to building, funding, and accelerating high-tech ventures.

Emma Howard, economics lecturer at Technical University of Dublin

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

What is building a large scale battery-powered aircraft was more feasible than originally thought?Our guest on this episode of the podcast, Daniel Rosen Jacobson co-founder and co-CEO of Elysian Aircraft, has come on the podcast to explain how asking the right questions and conducting scientific research laid the groundwork for the truly ambitious project that is the E9X electric airliner.While most electric aircraft projects have focused on the development of smaller aircraft, Elysian Aircraft is taking on the mainstream air travel market with a zero-emissions aircraft concept capable of carrying up to 90 passengers over distances of 1,000 kilometers.This is certainly a bold proposition, but one that, Daniel explains, is well grounded in science and engineering principles laid out by two papers co-authored by researchers at the Technical University of Delft, in The Netherlands.What's more, Elysian Aircraft is backed by Panta Holdings, a company that is no strangers to the world of aviation since it is the owner of Fokker Services Group, which is the remaining part of the iconic Dutch aircraft maker of the same name, now providing a range of MRO and other technical services to aircraft operators. Elysian's take on the future of zero emissions aircraft has also attracted the interest of consolidated industry players such as the Air France-KLM group and leasing firm TrueNoord, both of which have signed collaboration agreements with Elysian Aircraft with a view to potentially using the E9X aircraft one day in the future.This will, for now, have to wait a few years, as Elysian Aircraft refines its concept and builds and tests its first prototypes. In the meantime, though, we can listen to Elysian Aircraft's co-founder and co-CEO, Daniel Rosen Jacobson, explaining the key elements of this projected aircraft and the role he expects it to play in the future of commercial aviation!

In this episode, I reconnect with Prof. Ruth Oldenziel from the Technical University in Eindhoven for a discussion about the global Cycling Cities Initiative, which kicked off in 2016 with the publication  of the Cycling Cities: The European Experience coffee table book, which I happen to have in my house. We talk about the maturation of the project, including the upcoming release of the Cycling Cities: The African Experience, as well as the first from North America, Minneapolis. Helpful Links (note that some may include affiliate links to help me support the channel):

In this episode, we speak with Ashmi Banerjee, a doctoral candidate at the Technical University of Munich, about her pioneering research on AI-powered recommender systems in tourism. Ashmi illuminates how these systems can address exposure bias while promoting more sustainable tourism practices through innovative approaches to data acquisition and algorithm design.  Key highlights include leveraging large language models for synthetic data generation, developing recommendation architectures that balance user satisfaction with environmental concerns, and creating frameworks that distribute tourism more equitably across destinations. Ashmi's insights offer valuable perspectives for both AI researchers and tourism industry professionals seeking to implement more responsible recommendation technologies.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering: The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche. How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side. How Fujifilm's culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised. Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating. Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.    Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan.    Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies' global facilities regardless of geographical differences.   Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master's degree from the Technical University of Denmark.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! 

Are you a night owl or a morning lark?For many of us the traditional working day just doesn't suit our circadian rhythms. We're called into a meeting or slumped over a desk at 8am but hyper focused as we're about to leave the office and head home. What if work took our biological clocks into account?In this episode I am joined by Camilla Kring, author of Chrono leadership. We talk about the costs of rigidity in work patterns, and what it takes to develop smarter, more flexible arrangements.Camilla's ideas are revolutionary; she talks about taking the bias away from the 5am club and creating better conditions in the workplace for all. Surely that is something we would all want to get behind.So, when do you perform at your best during the day?“Synchronise your work, family, and biological rhythms for real performance.” - CamillaYou'll hear about:·      How circadian rhythms dictate our natural sleep and wake cycles.·      Why understanding your chronotype can enhance productivity.·      The fact most people are not morning persons, yet workplaces favour early risers.·      How living out of sync with your internal clock can harm health.·      Flexibility in work hours can lead to higher productivity and well-being.·      Trust in employees being crucial for implementing flexible work schedules.·      Why synchronising work and family rhythms can improve life quality. More about Camilla:Camilla Kring, as the founder of Super Navigators, has dedicated the last 20 years to helping individuals navigate their lives and organisations create flexible and inclusive work cultures that accommodate different chronotypes and family structures. She has worked across Europe, China, Latin America and the Middle East with companies including Abbott, Medtronic, Roche and Novo Nordisk.Camilla's insights have been featured in the New York Times, the BBC and the Guardian. She is the author of six books and a TEDx speaker. She holds a Master of Science in Engineering and a PhD in work-life balance from the Technical University of Denmark (DTU). Resources:• Profile: https://www.camillakring.com/about-camilla/ • Book - Chronoleadership: https://www.camillakring.com/books/ • Supernavigators services: https://www.supernavigators.com/   My resources:Try my High-stakes meetings toolkit (https://bit.ly/43cnhnQ) Take my Becoming a Strategic Leader course (https://bit.ly/3KJYDTj)Sign up to my Every Day is a Strategy Day newsletter (http://bit.ly/36WRpri) for modern mindsets and practices to help you get ahead.Subscribe to my YouTube channel (http://bit.ly/3cFGk1k) where you can watch the conversation.For more details about me:●      Services (https://rb.gy/ahlcuy) to CEOs, entrepreneurs and professionals.●      About me (https://rb.gy/dvmg9n) - my background, experience and philosophy.●      Examples of my writing https://rb.gy/jlbdds)●      Follow me and engage with me on LinkedIn (https://bit.ly/2Z2PexP)●      Follow me and engage with me on Twitter (https://bit.ly/36XavNI)

What defines a megaproject? And why do they so often go over both budget and schedule?   Denmark has earned a reputation for successfully completing large-scale construction projects – whether they are bridges, tunnels, land reclamation or offshore wind farms. The latest Danish megaproject is the Fehmarnbelt Fixed Link, a record-breaking 18-kilometer tunnel currently being placed on the seabed from the island of Lolland to Northern Germany.  In this episode, Michael Booth joins Professor Christian Langhoff Thuesen of Denmark's Technical University on a visit to the construction site of the Fehmarnbelt Fixed Link. Together they explore the impressive scale of the project and discuss the future of megaprojects in light of growing sustainability demands.   Let's Talk Architecture is a podcast by Danish Architecture Center. Sound edits by Munck Studios. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Michael Scholl, Chief Executive Officer and Co-Founder at Leukocare. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michael, covering: The influences, and potential for impact that led him down a path of entrepreneurship. Chronicling the ups and downs of over 20 years in business at Leukocare. Pivoting to be a specialist CRO/CDMO with a differentiation in data-driven, formulation development... leading to a record year in 2024. How the delay in decision making in the market is impacting the pharma services space. Michael Scholl is the Co-founder and Chief Executive Officer of Leukocare, a leading CDMO specializing in formulation and drug product development services for sterile injectables. With more than 20 years of leadership experience in the life sciences industry, Michael is responsible for shaping the company's strategic direction and cultivating partnerships with biopharmaceutical clients around the world. Under his leadership, Leukocare has established itself as a trusted partner in advancing complex biologics from early development to market-ready drug products. He began his career as a business consultant at the Boston Consulting Group (BCG), he holds a degree in Industrial Engineering from the Technical University of Berlin and studied at the Haas School of Business, University of California, Berkeley.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Before CRISPR-based methods took center stage in the genome editing field, other bio-inspired tools such as zinc finger nucleases and Cre-lox system recombinases made genomic engineering possible. Some researchers are now looking back to these foundational technologies to improve upon and one-up the latest gene editing techniques.  In this episode, Deanna MacNeil from The Scientist spoke with Frank Buchholz, professor and head of the medical systems biology translational research group at the Technical University of Dresden's University Cancer Center, to explore how his laboratory designs programmable recombinases for high fidelity gene editing.   The Scientist Speaks is a podcast produced by The Scientist's Creative Services Team. Our podcast is by scientists and for scientists. We bring you the stories behind news-worthy molecular biology research. This episode is brought to you by Oxford Nanopore.

Can science turn any blood into a universal donor type? Join us in this episode as we explore groundbreaking healthcare innovations with Maher Abou Hachem, a distinguished Professor in the Department of Biotechnology and Biomedicine at the Technical University of Denmark. Maher's expertise spans recombinant protein production, purification, biomolecular interactions, stability, and enzymology. From gut microbiome studies to pioneering blood type conversion, his cutting-edge research is reshaping the future of healthcare. Are you ready to find out what makes Maher's work so unique? Hit play to find out! Dive in now to discover: What the major blood types are, and how they are used in transfusion and transplant applications. What happens if you give the wrong blood type to a patient. How researchers can change one blood type to another. The significance of red blood cells in the human body. You can learn more about Maher and his investigations here! Episode also available on Apple Podcasts: http://apple.co/30PvU9